

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
29 July 2004 (29.07.2004)

PCT

(10) International Publication Number
WO 2004/063219 A1

(51) International Patent Classification⁷: C07K 14/47, C12N 15/12, G01N 33/566, C12Q 1/68, A61K 38/17, A01K 67/027

[GB/GB]; Inpharmatica Limited, 60 Charlotte Street, London W1T 2NU (GB). POWER, Christine [GB/FR]; 10, rue des Jonquilles, 01710 Thoiry (FR). YORKE, Melanie [GB/CH]; 20a Chemin de Vuillonnex, CH-1232 Confignon (CH).

(21) International Application Number:
PCT/GB2004/000101

(74) Agents: GOODFELLOW, Hugh, Robin et al.; Carpmaels & Ransford, 43-45 Bloomsbury Square, London WC1A 2RA (GB).

(22) International Filing Date: 13 January 2004 (13.01.2004)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
0300718.4 13 January 2003 (13.01.2003) GB

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

(71) Applicant (for all designated States except US): ARES TRADING S.A. [CH/CH]; Chateau de Vaumarcus, CH-2028 Vaumarcus (CH).
(72) Inventors; and
(75) Inventors/Applicants (for US only): FAGAN, Richard, Joseph [US/GB]; Inpharmatica Limited, 60 Charlotte Street, London W1T 2NU (GB). MICHALOVICH, David [GB/GB]; Inpharmatica Limited, 60 Charlotte Street, London W1T 2NU (GB). WHITE, Simon, John

(54) Title: DEFENSIN PROTEINS

Predicted nucleotide sequence of INSP108 with translation

1 ttgttccaaa aggttcacta gccatgcagc tccccgtctc ttcaaagctg cggagagagt
61 gactctccga tgagtcacag ctgtttttt gctgatttgt atggccacaa ggagcgctct
m a t r s v
INSP108-F1

121 cttggccctc gtggcctta acttacttctt ctatgttcca ccaggttagaa gtggacccaa
1 i a l v v l n i l f y v p p g r s g p

181 tgtctacata caaaaaatct ttgcttcatg ttggcactg caaggtactt gccggccaaa
n v y i q k i f a s c w r i q g t c r p

241 atgtctaaaa aaccaacaat atcgatatttt gtgtgatact atacatttgt gctgtgtaaa
k c l k n e q y r i i c d t i h l c c v

301 cccaaaatat ttacctatac tgactggaa atagttgtga gtacctgaaa gctgttgctg
n p k y l p i l t g k
INSP108-R1

361 atttcctctg ggaacccaga tccctctcag ttgcaccatt cgattaaaac aatggctta
421 gcctatcagt gttc

Position and sense of PCR primers →
Underlined: signal sequence

WO 2004/063219 A1

(57) Abstract: This invention relates to the novel proteins, termed INSP 108 and INSP 109, herein identified as members of the defensin family of proteins and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.

BEST AVAILABLE COPY



Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Defensin Proteins

This invention relates to the novel proteins, termed INSP108 and INSP109, herein identified as secreted proteins, in particular, as members of the defensin family of proteins and to the use of these proteins and nucleic acid sequences from the encoding genes in the 5 diagnosis, prevention and treatment of disease.

All publications, patents and patent applications cited herein are incorporated in full by reference.

Background

The process of drug discovery is presently undergoing a fundamental revolution as the era 10 of functional genomics comes of age. The term "functional genomics" applies to an approach utilising bioinformatics tools to ascribe function to protein sequences of interest. Such tools are becoming increasingly necessary as the speed of generation of sequence data is rapidly outpacing the ability of research laboratories to assign functions to these protein sequences.

15 As bioinformatics tools increase in potency and in accuracy, these tools are rapidly advanced bioinformatics tools used in identifying the present invention are now capable of outputting results in which a high degree of confidence can be placed.

Various institutions and commercial organisations are examining sequence data as they 20 become available and significant discoveries are being made on an on-going basis. However, there remains a continuing need to identify and characterise further genes and the polypeptides that they encode, as targets for research and for drug discovery.

Introduction

Secreted Proteins

25 The ability for cells to make and secrete extracellular proteins is central to many biological processes. Enzymes, growth factors, extracellular matrix proteins and signalling molecules are all secreted by cells. This is through fusion of a secretory vesicle with the plasma membrane. In most cases, but not all, proteins are directed to the endoplasmic reticulum and into secretory vesicles by a signal peptide. Signal peptides are cis-acting sequences 30 that affect the transport of polypeptide chains from the cytoplasm to a membrane bound

compartment such as a secretory vesicle. Polypeptides that are targeted to the secretory vesicles are either secreted into the extracellular matrix or are retained in the plasma membrane. The polypeptides that are retained in the plasma membrane will have one or more transmembrane domains. Examples of secreted proteins that play a central role in the functioning of a cell are cytokines, hormones, extracellular matrix proteins (adhesion molecules), proteases, and growth and differentiation factors. Description of some of the properties of these proteins follows.

Defensins

Defensins form part of the body's innate immune system that acts against invasion by foreign pathogens. Mammalian defensins are split into three categories; alpha, beta and theta, based upon the pattern of disulphide bonds. INSP108 and INSP109 fall into the beta category. These proteins are cationic and arginine-rich and share a typical tertiary structure despite differences in primary structure. They consist of three antiparallel beta sheets connected by loops, and a beta hairpin with hydrophobic properties protrudes orthogonally.

These proteins have been shown to have a broad spectrum of activity ranging from Gram-

They bind to the phospholipid-rich negatively charged cell membranes of microbes and cause disruption, though the exact mode of action is yet to be determined. High concentrations are cytotoxic for mammalian cells, though it has been shown that lower concentrations promote growth in epithelial cells and fibroblasts, thus suggesting a role in wound healing. Defensins have also been shown to be chemotactic for monocytes, polymorphonuclear leucocytes and T-cells. *In vitro* defensins have been shown to be active against *E. coli*, *Listeria monocytogenes*, *Salmonella typhimurium* and *Candida albicans*.

Increasing knowledge of these proteins is therefore of extreme importance in increasing the understanding of the underlying pathways that lead to the disease states and associated disease states mentioned above, and in developing more effective gene and/or drug therapies to treat these disorders.

THE INVENTION

The invention is based on the discovery that the INSP108 and INSP109 polypeptides are defensins.

In one embodiment of the first aspect of the invention, there is provided a polypeptide which:

- (i) comprises the amino acid sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 and/or SEQ ID NO:8;
- 5 (ii) is a fragment thereof which functions as a member of the defensin family of proteins, or has an antigenic determinant in common with the polypeptides of (i); or
- (iii) is a functional equivalent of (i) or (ii).

Preferably, the polypeptide according to this first aspect of the invention:

- (i) comprises the amino acid sequence as recited in SEQ ID NO:6 and/or SEQ ID NO:8;
- (ii) is a fragment thereof which functions as a member of the defensin family of proteins, or has an antigenic determinant in common with the polypeptides of (i); or
- (iii) is a functional equivalent of (i) or (ii).

According to a second embodiment of this first aspect of the invention, there is provided a

- (i) consists of the amino acid sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 and/or SEQ ID NO:8;
- 20 (ii) is a fragment thereof which functions as a member of the defensin family of proteins, or having an antigenic determinant in common with the polypeptides of (i); or
- (iii) is a functional equivalent of (i) or (ii).

The polypeptide having the sequence recited in SEQ ID NO:2 is referred to hereafter as "INSP108 exon 1 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:4 is referred to hereafter as "INSP108 exon 2 polypeptide". The polypeptide having 25 the sequence recited in SEQ ID NO:6 is referred to hereafter as the "INSP108 polypeptide".

Although the Applicant does not wish to be bound by this theory, it is postulated that the first 24 amino acids of the INSP108 polypeptide form a signal peptide.

The full length INSP108 polypeptide sequences without this postulated signal sequence is

recited in SEQ ID NO:8.

The polypeptide having the sequence recited in SEQ ID NO:8 is referred to hereafter as "the INSP108 mature polypeptide".

The term "INSP108 polypeptides" as used herein includes polypeptides comprising the
5 INSP108 exon 1 polypeptide, the INSP108 exon 2 polypeptide, the INSP108 polypeptide
and the INSP108 mature polypeptide.

In a third embodiment of the first aspect of the invention, there is provided a polypeptide which:

- (i) comprises the amino acid sequence as recited in SEQ ID NO:10, SEQ ID NO:12,
10 SEQ ID NO:14 and/or SEQ ID NO:16;
- (ii) is a fragment thereof which functions as a member of the defensin family of proteins, or has an antigenic determinant in common with the polypeptides of (i); or
- (iii) is a functional equivalent of (i) or (ii).

Preferably, the polypeptide according to this first aspect of the invention:

- NO:16;
- (ii) is a fragment thereof which functions as a member of the defensin family of proteins, or has an antigenic determinant in common with the polypeptides of (i); or
- (iii) is a functional equivalent of (i) or (ii).
- 20 According to a fourth embodiment of this first aspect of the invention, there is provided a polypeptide which:
- (i) consists of the amino acid sequence as recited in SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14 and/or SEQ ID NO:16;
- (ii) is a fragment thereof which functions as a member of the defensin family of proteins, or having an antigenic determinant in common with the polypeptides of
25 (i); or
- (iii) is a functional equivalent of (i) or (ii).

The polypeptide having the sequence recited in SEQ ID NO:10 is referred to hereafter as "INSP109 exon 1 polypeptide". The polypeptide having the sequence recited in SEQ ID

NO:12 is referred to hereafter as "INSP109 exon 2 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:14 is referred to hereafter as the "INSP109 polypeptide".

Although the Applicant does not wish to be bound by this theory, it is postulated that the
5 first 21 amino acids of the INSP109 polypeptide form a signal peptide.

The full length INSP109 polypeptide sequences without this postulated signal sequence is recited in SEQ ID NO:16.

The polypeptide having the sequence recited in SEQ ID NO:16 is referred to hereafter as "the INSP109 mature polypeptide".

10 The term "INSP109 polypeptides" as used herein includes polypeptides comprising the INSP109 exon 1 polypeptide, the INSP109 exon 2 polypeptide, the INSP109 polypeptide and the INSP109 mature polypeptide.

By "functions as a member of the defensin family" we refer to polypeptides that comprise amino acid sequence or structural features that can be identified as conserved features
15 within the polypeptides of the defensin family, such that the polypeptide's interaction with

of the full length wild type polypeptide. In particular, we refer to the presence of cysteine residues in specific positions within the polypeptide that allow the formation of intra-domain disulphide bonds. Ability to function as a defensin may be measured using the
20 assays described by Nizet *et al.* (Nature 2001, 414:454-457) and Cole *et al.* (Proc. Natl. Acad. Sci. 2002, 99(4):1813-1818).

In a second aspect, the invention provides a purified nucleic acid molecule which encodes a polypeptide of the first aspect of the invention.

Preferably, the purified nucleic acid molecule comprises the nucleic acid sequence as
25 recited in SEQ ID NO:1 (encoding the INSP108 exon 1 polypeptide), SEQ ID NO:3 (encoding the INSP108 exon 2 polypeptide), SEQ ID NO:5 (encoding the INSP108 polypeptide), SEQ ID NO:7 (encoding the INSP108 mature polypeptide), SEQ ID NO:9 (encoding the INSP109 exon 1 polypeptide), SEQ ID NO:11 (encoding the INSP109 exon 2 polypeptide), SEQ ID NO:13 (encoding the INSP109 polypeptide) and/or SEQ ID
30 NO:15 (encoding the INSP109 mature polypeptide) or is a redundant equivalent or fragment of any one of these sequences.

The invention further provides that the purified nucleic acid molecule consists of the nucleic acid sequence as recited in SEQ ID NO:1 (encoding the INSP108 exon 1 polypeptide), SEQ ID NO:3 (encoding the INSP108 exon 2 polypeptide), SEQ ID NO:5 (encoding the INSP108 polypeptide), SEQ ID NO:7 (encoding the INSP108 mature polypeptide), SEQ ID NO:9 (encoding the INSP109 exon 1 polypeptide), SEQ ID NO:11 (encoding the INSP109 exon 2 polypeptide), SEQ ID NO:13 (encoding the INSP109 polypeptide) and/or SEQ ID NO:15 (encoding the INSP109 mature polypeptide) or is a redundant equivalent or fragment of any one of these sequences.

In a third aspect, the invention provides a purified nucleic acid molecule which hybridizes under high stringency conditions with a nucleic acid molecule of the second aspect of the invention.

In a fourth aspect, the invention provides a vector, such as an expression vector, that contains a nucleic acid molecule of the second or third aspect of the invention.

In a fifth aspect, the invention provides a host cell transformed with a vector of the fourth aspect of the invention.

members of the defensin family of the first aspect of the invention. Preferably, the ligand inhibits the function of a polypeptide of the first aspect of the invention which is a member of the defensin family of proteins. Ligands to a polypeptide according to the invention may come in various forms, including natural or modified substrates, enzymes, receptors, small organic molecules such as small natural or synthetic organic molecules of up to 2000Da, preferably 800Da or less, peptidomimetics, inorganic molecules, peptides, polypeptides, antibodies, structural or functional mimetics of the aforementioned.

In a seventh aspect, the invention provides a compound that is effective to alter the expression of a natural gene which encodes a polypeptide of the first aspect of the invention or to regulate the activity of a polypeptide of the first aspect of the invention.

A compound of the seventh aspect of the invention may either increase (agonise) or decrease (antagonise) the level of expression of the gene or the activity of the polypeptide.

Importantly, the identification of the functions of the INSP108 and INSP109 polypeptides allows for the design of screening methods capable of identifying compounds that are effective in the treatment and/or diagnosis of disease. Ligands and compounds according to

the sixth and seventh aspects of the invention may be identified using such methods. These methods are included as aspects of the present invention.

In an eighth aspect, the invention provides a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention, for use in therapy or diagnosis of diseases in which members of the defensin family are implicated. Such diseases may include cell proliferative disorders, including neoplasm, melanoma, lung, colorectal, breast, pancreas, head and neck and other solid tumours; myeloproliferative disorders, such as leukemia, non-Hodgkin lymphoma, leukopenia, thrombocytopenia, angiogenesis disorder, Kaposi's sarcoma; autoimmune/inflammatory disorders, including allergy, inflammatory bowel disease, arthritis, psoriasis and respiratory tract inflammation, asthma, and organ transplant rejection; cardiovascular disorders, including hypertension, oedema, angina, atherosclerosis, thrombosis, sepsis, shock, reperfusion injury, and ischemia; neurological disorders including central nervous system disease, Alzheimer's disease, brain injury, including diabetes mellitus, osteoporosis, and obesity, AIDS and renal disease; infections including viral infection, bacterial infection, fungal infection and parasitic infection and other pathological conditions. Preferably, the disease is one in which the defensin family of proteins is implicated, such as sublethal endotoxaemia, septic shock, microbial infection of the amniotic cavity, Jarish-Herxheimer reaction of relapsing fever, infectious diseases of the central nervous system, acute pancreatitis, ulcerative colitis, empyema, haemolytic uraemic syndrome, meningococcal disease, gastric infection, pertussis, peritonitis, psoriasis, rheumatoid arthritis, sepsis, asthma, HIV, AIDS and glomerulonephritis. These molecules may also be used in the manufacture of a medicament for the treatment of such diseases.

In a ninth aspect, the invention provides a method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide of the first aspect of the invention or the activity of a polypeptide of the first aspect of the invention in tissue from said patient and comparing said level of expression or activity to a control level, wherein a level that is different to said control level is indicative of disease. Such a method will preferably be carried out *in vitro*. Similar methods may be used for

monitoring the therapeutic treatment of disease in a patient, wherein altering the level of expression or activity of a polypeptide or nucleic acid molecule over the period of time towards a control level is indicative of regression of disease.

A preferred method for detecting polypeptides of the first aspect of the invention 5 comprises the steps of: (a) contacting a ligand, such as an antibody, of the sixth aspect of the invention with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.

A number of different such methods according to the ninth aspect of the invention exist, as the skilled reader will be aware, such as methods of nucleic acid hybridization with short 10 probes, point mutation analysis, polymerase chain reaction (PCR) amplification and methods using antibodies to detect aberrant protein levels. Similar methods may be used on a short or long term basis to allow therapeutic treatment of a disease to be monitored in a patient. The invention also provides kits that are useful in these methods for diagnosing disease.

- 15 In a tenth aspect, the invention provides for the use of a polypeptide of the first aspect of the invention as a defensin protein. Suitable uses of the polypeptides of the invention as ~~defensin proteins include use as a regulator of cellular growth, induction of differentiation, use as part of a receptor/ligand pair and use as a diagnostic marker for a physiological or pathological condition selected from the list given above.~~
- 20 In an eleventh aspect, the invention provides a pharmaceutical composition comprising a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention, in conjunction with a pharmaceutically-
25 acceptable carrier.

In a twelfth aspect, the present invention provides a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh 30 aspect of the invention, for use in the manufacture of a medicament for the diagnosis or treatment of a disease.

In a thirteenth aspect, the invention provides a method of treating a disease in a patient comprising administering to the patient a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand 5 of the sixth aspect of the invention, or a compound of the seventh aspect of the invention.

For diseases in which the expression of a natural gene encoding a polypeptide of the first aspect of the invention, or in which the activity of a polypeptide of the first aspect of the invention, is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, ligand or compound 10 administered to the patient should be an agonist. Conversely, for diseases in which the expression of the natural gene or activity of the polypeptide is higher in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, ligand or compound administered to the patient should be an antagonist. Examples of such antagonists include antisense nucleic acid molecules, 15 ribozymes and ligands, such as antibodies.

In a fourteenth aspect, the invention provides transgenic or knockout non-human animals first aspect of the invention. Such transgenic animals are very useful models for the study 20 of disease and may also be used in screening regimes for the identification of compounds that are effective in the treatment or diagnosis of such a disease.

A summary of standard techniques and procedures which may be employed in order to utilise the invention is given below. It will be understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors and reagents described. It is also to be understood that the terminology used herein is for the purpose of describing 25 particular embodiments only and it is not intended that this terminology should limit the scope of the present invention. The extent of the invention is limited only by the terms of the appended claims.

Standard abbreviations for nucleotides and amino acids are used in this specification.

The practice of the present invention will employ, unless otherwise indicated, conventional 30 techniques of molecular biology, microbiology, recombinant DNA technology and immunology, which are within the skill of those working in the art.

Such techniques are explained fully in the literature. Examples of particularly suitable texts for consultation include the following: Sambrook Molecular Cloning; A Laboratory Manual, Second Edition (1989); DNA Cloning, Volumes I and II (D.N Glover ed. 1985); Oligonucleotide Synthesis (M.J. Gait ed. 1984); Nucleic Acid Hybridization (B.D. Hames & S.J. Higgins eds. 1984); Transcription and Translation (B.D. Hames & S.J. Higgins eds. 1984); Animal Cell Culture (R.I. Freshney ed. 1986); Immobilized Cells and Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide to Molecular Cloning (1984); the Methods in Enzymology series (Academic Press, Inc.), especially volumes 154 & 155; Gene Transfer Vectors for Mammalian Cells (J.H. Miller and M.P. Calos eds. 1987, Cold Spring Harbor Laboratory); Immunochemical Methods in Cell and Molecular Biology (Mayer and Walker, eds. 1987, Academic Press, London); Scopes, (1987) Protein Purification: Principles and Practice, Second Edition (Springer Verlag, N.Y.); and Handbook of Experimental Immunology, Volumes I-IV (D.M. Weir and C. C. Blackwell eds. 1986).

As used herein, the term "polypeptide" includes any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, *i.e.* peptide isosteres. This term refers both to short chains (peptides and oligopeptides) and to

The polypeptide of the present invention may be in the form of a mature protein or may be a pre-, pro- or prepro- protein that can be activated by cleavage of the pre-, pro- or prepro- portion to produce an active mature polypeptide. In such polypeptides, the pre-, pro- or prepro- sequence may be a leader or secretory sequence or may be a sequence that is employed for purification of the mature polypeptide sequence.

The polypeptide of the first aspect of the invention may form part of a fusion protein. For example, it is often advantageous to include one or more additional amino acid sequences which may contain secretory or leader sequences, pro-sequences, sequences which aid in purification, or sequences that confer higher protein stability, for example during recombinant production. Alternatively or additionally, the mature polypeptide may be fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol).

Polypeptides may contain amino acids other than the 20 gene-encoded amino acids, modified either by natural processes, such as by post-translational processing or by chemical modification techniques which are well known in the art. Among the known

modifications which may commonly be present in polypeptides of the present invention are glycosylation, lipid attachment, sulphation, gamma-carboxylation, for instance of glutamic acid residues, hydroxylation and ADP-ribosylation. Other potential modifications include acetylation, acylation, amidation, covalent attachment of flavin, covalent 5 attachment of a haeme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulphide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, GPI anchor formation, iodination, methylation, myristoylation, oxidation, 10 proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. In fact, blockage of the amino or carboxyl terminus in a polypeptide, or both, by a covalent modification is common in 15 naturally-occurring and synthetic polypeptides and such modifications may be present in polypeptides of the present invention.

polypeptide is made. For polypeptides that are made recombinantly, the nature and extent of the modifications in large part will be determined by the post-translational modification 20 capacity of the particular host cell and the modification signals that are present in the amino acid sequence of the polypeptide in question. For instance, glycosylation patterns vary between different types of host cell.

The polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally-occurring polypeptides (for example purified from 25 cell culture), recombinantly-produced polypeptides (including fusion proteins), synthetically-produced polypeptides or polypeptides that are produced by a combination of these methods.

The functionally-equivalent polypeptides of the first aspect of the invention may be polypeptides that are homologous to the INSP108 or INSP109 polypeptides. Two 30 polypeptides are said to be "homologous", as the term is used herein, if the sequence of one of the polypeptides has a high enough degree of identity or similarity to the sequence of the other polypeptide. "Identity" indicates that at any particular position in the aligned

- sequences, the amino acid residue is identical between the sequences. "Similarity" indicates that, at any particular position in the aligned sequences, the amino acid residue is of a similar type between the sequences. Degrees of identity and similarity can be readily calculated (Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, 5 New York, 1988; Biocomputing. Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heijne, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991).
- 10 Homologous polypeptides therefore include natural biological variants (for example, allelic variants or geographical variations within the species from which the polypeptides are derived) and mutants (such as mutants containing amino acid substitutions, insertions or deletions) of the INSP108 and INSP109 polypeptides. Such mutants may include 15 polypeptides in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the

Thr; among the acidic residues Asp and Glu; among Asn and Gln; among the basic residues Lys and Arg; or among the aromatic residues Phe and Tyr. Particularly preferred 20 are variants in which several, *i.e.* between 5 and 10, 1 and 5, 1 and 3, 1 and 2 or just 1 amino acids are substituted, deleted or added in any combination. Especially preferred are silent substitutions, additions and deletions, which do not alter the properties and activities of the protein. Also especially preferred in this regard are conservative substitutions. Such 25 mutants also include polypeptides in which one or more of the amino acid residues includes a substituent group.

Typically, greater than 30% identity between two polypeptides is considered to be an indication of functional equivalence. Preferably, functionally equivalent polypeptides of the first aspect of the invention have a degree of sequence identity with the INSP108 and INSP109 polypeptides, or with active fragments thereof, of greater than 80%. More 30 preferred polypeptides have degrees of identity of greater than 85%, 90%, 95%, 98% or 99%, respectively.

The functionally-equivalent polypeptides of the first aspect of the invention may also be

polypeptides which have been identified using one or more techniques of structural alignment. For example, the Inpharmatica Genome Threader technology that forms one aspect of the search tools used to generate the Biopendium™ search database may be used (see PCT application WO 01/69507) to identify polypeptides of presently-unknown function which, while having low sequence identity as compared to the INSP108 and INSP109 polypeptides, are predicted to be members of the defensin family, by virtue of sharing significant structural homology with the INSP108 and INSP109 polypeptide sequences. By "significant structural homology" is meant that the Inpharmatica Genome Threader predicts two proteins to share structural homology with a certainty of 10% and above.

The polypeptides of the first aspect of the invention also include fragments of the INSP108 or INSP109 polypeptides and fragments of the functional equivalents of the INSP108 or INSP109 polypeptides, provided that those fragments are members of the defensin family or have an antigenic determinant in common with the INSP108 or INSP109 polypeptides.

As used herein, the term "fragment" refers to a polypeptide having an amino acid sequence that is the same as part, but not all, of the amino acid sequence of the INSP108 or INSP109 polypeptides. A fragment is a sequence of n consecutive amino acids from the sequence and, depending on the particular sequence, n preferably is 7 or more (for example, 8, 10, 12, 14, 16, 18, 20 or more). Small fragments may form an antigenic determinant.

Fragments of the full length INSP108 and INSP109 polypeptides may consist of combinations of 1 or 2 of neighbouring exon sequences in the INSP108 or INSP109 polypeptide sequences, respectively. For example, such combinations include exons 1 and 2 of the INSP108 polypeptide. Such fragments are included in the present invention.

Such fragments may be "free-standing", *i.e.* not part of or fused to other amino acids or polypeptides, or they may be comprised within a larger polypeptide of which they form a part or region. When comprised within a larger polypeptide, the fragment of the invention most preferably forms a single continuous region. For instance, certain preferred embodiments relate to a fragment having a pre- and/or pro- polypeptide region fused to the amino terminus of the fragment and/or an additional region fused to the carboxyl terminus of the fragment. However, several fragments may be comprised within a single larger polypeptide.

The polypeptides of the present invention or their immunogenic fragments (comprising at least one antigenic determinant) can be used to generate ligands, such as polyclonal or monoclonal antibodies, that are immunospecific for the polypeptides. Such antibodies may be employed to isolate or to identify clones expressing the polypeptides of the invention or

5 to purify the polypeptides by affinity chromatography. The antibodies may also be employed as diagnostic or therapeutic aids, amongst other applications, as will be apparent to the skilled reader.

The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the

10 prior art. As used herein, the term "antibody" refers to intact molecules as well as to fragments thereof, such as Fab, F(ab')² and Fv, which are capable of binding to the antigenic determinant in question. Such antibodies thus bind to the polypeptides of the first aspect of the invention.

By "substantially greater affinity" we mean that there is a measurable increase in the

15 affinity for a polypeptide of the invention as compared with the affinity for known secreted proteins.

Preferably, the affinity is at least 1.0-fold, 2-fold, 3-fold 10-fold, 100-fold, 10³-fold, 10⁴-fold, 10⁵-fold, 10⁶-fold or greater for a polypeptide of the invention than for known secreted proteins such as members of the defensin family of proteins.

20 If polyclonal antibodies are desired, a selected mammal, such as a mouse, rabbit, goat or horse, may be immunised with a polypeptide of the first aspect of the invention. The polypeptide used to immunise the animal can be derived by recombinant DNA technology or can be synthesized chemically. If desired, the polypeptide can be conjugated to a carrier protein. Commonly used carriers to which the polypeptides may be chemically coupled

25 include bovine serum albumin, thyroglobulin and keyhole limpet haemocyanin. The coupled polypeptide is then used to immunise the animal. Serum from the immunised animal is collected and treated according to known procedures, for example by immunoaffinity chromatography.

Monoclonal antibodies to the polypeptides of the first aspect of the invention can also be

30 readily produced by one skilled in the art. The general methodology for making monoclonal antibodies using hybridoma technology is well known (see, for example, Kohler, G. and Milstein, C., *Nature* 256: 495-497 (1975); Kozbor *et al.*, *Immunology*

Today 4: 72 (1983); Cole *et al.*, 77-96 in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985).

Panels of monoclonal antibodies produced against the polypeptides of the first aspect of the invention can be screened for various properties, *i.e.*, for isotype, epitope, affinity, etc.

- 5 Monoclonal antibodies are particularly useful in purification of the individual polypeptides against which they are directed. Alternatively, genes encoding the monoclonal antibodies of interest may be isolated from hybridomas, for instance by PCR techniques known in the art, and cloned and expressed in appropriate vectors.

Chimeric antibodies, in which non-human variable regions are joined or fused to human
10 constant regions (see, for example, Liu *et al.*, Proc. Natl. Acad. Sci. USA, 84, 3439 (1987)), may also be of use.

The antibody may be modified to make it less immunogenic in an individual, for example by humanisation (see Jones *et al.*, Nature, 321, 522 (1986); Verhoeyen *et al.*, Science, 239, 1534 (1988); Kabat *et al.*, J. Immunol., 147, 1709 (1991); Queen *et al.*, Proc. Natl Acad. Sci. USA, 86, 10029 (1989); Gorman *et al.*, Proc. Natl Acad. Sci. USA, 88, 34181 (1991); and Henderson *et al.* BioTechnology 9 421 (1991)). The term "humanised antibody", as used herein, refers to antibody molecules in which the original amino acids have been replaced by other amino acids in the variable domains of the heavy and/or light chains of a non-human donor antibody have been substituted in place of the equivalent amino acids in a human antibody.
20 The humanised antibody thus closely resembles a human antibody but has the binding ability of the donor antibody.

In a further alternative, the antibody may be a "bispecific" antibody, that is an antibody having two different antigen binding domains, each domain being directed against a different epitope.

- 25 Phage display technology may be utilised to select genes which encode antibodies with binding activities towards the polypeptides of the invention either from repertoires of PCR amplified V-genes of lymphocytes from humans screened for possessing the relevant antibodies, or from naive libraries (McCafferty, J. *et al.*, (1990), Nature 348, 552-554; Marks, J. *et al.*, (1992) Biotechnology 10, 779-783). The affinity of these antibodies can
30 also be improved by chain shuffling (Clackson, T. *et al.*, (1991) Nature 352, 624-628).

Antibodies generated by the above techniques, whether polyclonal or monoclonal, have

additional utility in that they may be employed as reagents in immunoassays, radioimmunoassays (RIA) or enzyme-linked immunosorbent assays (ELISA). In these applications, the antibodies can be labelled with an analytically-detectable reagent such as a radioisotope, a fluorescent molecule or an enzyme.

- 5 Preferred nucleic acid molecules of the second and third aspects of the invention are those which encode a polypeptide sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14 and SEQ ID NO:16 and functionally equivalent polypeptides. These nucleic acid molecules may be used in the methods and applications described herein. The nucleic acid molecules of the invention
10 preferably comprise at least n consecutive nucleotides from the sequences disclosed herein where, depending on the particular sequence, n is 10 or more (for example, 12, 14, 15, 18, 20, 25, 30, 35, 40 or more).

The nucleic acid molecules of the invention also include sequences that are complementary to nucleic acid molecules described above (for example, for antisense or probing
15 purposes).

Nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance linear, circular and supercoiled DNA. Such nucleic acid molecules may be obtained by cloning, by chemical synthetic techniques or by a combination thereof. The nucleic acid molecules can be prepared, for
20 example, by chemical synthesis using techniques such as solid phase phosphoramidite chemical synthesis, from genomic or cDNA libraries or by separation from an organism. RNA molecules may generally be generated by the *in vitro* or *in vivo* transcription of DNA sequences.

The nucleic acid molecules may be double-stranded or single-stranded. Single-stranded
25 DNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand.

The term "nucleic acid molecule" also includes analogues of DNA and RNA, such as those containing modified backbones, and peptide nucleic acids (PNA). The term "PNA", as used herein, refers to an antisense molecule or an anti-gene agent which comprises an
30 oligonucleotide of at least five nucleotides in length linked to a peptide backbone of amino acid residues, which preferably ends in lysine. The terminal lysine confers solubility to the composition. PNAs may be pegylated to extend their lifespan in a cell, where they

preferentially bind complementary single stranded DNA and RNA and stop transcript elongation (Nielsen, P.E. *et al.* (1993) *Anticancer Drug Des.* 8:53-63).

A nucleic acid molecule which encodes a polypeptide of this invention may be identical to the coding sequence of one or more of the nucleic acid molecules disclosed herein.

- 5 These molecules also may have a different sequence which, as a result of the degeneracy of the genetic code, encodes a polypeptide as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14 or SEQ ID NO:16. Such nucleic acid molecules may include, but are not limited to, the coding sequence for the mature polypeptide by itself; the coding sequence for the mature polypeptide and
- 10 additional coding sequences, such as those encoding a leader or secretory sequence, such as a pro-, pre- or prepro- polypeptide sequence; the coding sequence of the mature polypeptide, with or without the aforementioned additional coding sequences, together with further additional, non-coding sequences, including non-coding 5' and 3' sequences, such as the transcribed, non-translated sequences that play a role in transcription (including
- 15 termination signals), ribosome binding and mRNA stability. The nucleic acid molecules may also include additional sequences which encode additional amino acids, such as those

-
- The nucleic acid molecules of the second and third aspects of the invention may also encode the fragments or the functional equivalents of the polypeptides and fragments of
 - 20 the first aspect of the invention. Such a nucleic acid molecule may be a naturally-occurring variant such as a naturally-occurring allelic variant, or the molecule may be a variant that is not known to occur naturally. Such non-naturally occurring variants of the nucleic acid molecule may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells or organisms.
 - 25 Among variants in this regard are variants that differ from the aforementioned nucleic acid molecules by nucleotide substitutions, deletions or insertions. The substitutions, deletions or insertions may involve one or more nucleotides. The variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or insertions.
 - 30 The nucleic acid molecules of the invention can also be engineered, using methods generally known in the art, for a variety of reasons, including modifying the cloning, processing, and/or expression of the gene product (the polypeptide). DNA shuffling by

random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides are included as techniques which may be used to engineer the nucleotide sequences. Site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce 5 mutations and so forth.

- Nucleic acid molecules which encode a polypeptide of the first aspect of the invention may be ligated to a heterologous sequence so that the combined nucleic acid molecule encodes a fusion protein. Such combined nucleic acid molecules are included within the second or third aspects of the invention. For example, to screen peptide libraries for inhibitors of the 10 activity of the polypeptide, it may be useful to express, using such a combined nucleic acid molecule, a fusion protein that can be recognised by a commercially-available antibody. A fusion protein may also be engineered to contain a cleavage site located between the sequence of the polypeptide of the invention and the sequence of a heterologous protein so that the polypeptide may be cleaved and purified away from the heterologous protein.
- 15 The nucleic acid molecules of the invention also include antisense molecules that are partially complementary to nucleic acid molecules encoding polypeptides of the present

(hybridization). Such antisense molecules, such as oligonucleotides, can be designed to recognise, specifically bind to and prevent transcription of a target nucleic acid encoding a 20 polypeptide of the invention, as will be known by those of ordinary skill in the art (see, for example, Cohen, J.S., Trends in Pharm. Sci., 10, 435 (1989), Okano, J. Neurochem. 56, 560 (1991); O'Connor, J. Neurochem 56, 560 (1991); Lee *et al.*, Nucleic Acids Res 6, 3073 (1979); Cooney *et al.*, Science 241, 456 (1988); Dervan *et al.*, Science 251, 1360 (1991)).

The term "hybridization" as used here refers to the association of two nucleic acid 25 molecules with one another by hydrogen bonding. Typically, one molecule will be fixed to a solid support and the other will be free in solution. Then, the two molecules may be placed in contact with one another under conditions that favour hydrogen bonding. Factors that affect this bonding include: the type and volume of solvent; reaction temperature; time of hybridization; agitation; agents to block the non-specific attachment of the liquid phase 30 molecule to the solid support (Denhardt's reagent or BLOTO); the concentration of the molecules; use of compounds to increase the rate of association of molecules (dextran sulphate or polyethylene glycol); and the stringency of the washing conditions following

hybridization (see Sambrook *et al.* [*supra*]).

The inhibition of hybridization of a completely complementary molecule to a target molecule may be examined using a hybridization assay, as known in the art (see, for example, Sambrook *et al.* [*supra*]). A substantially homologous molecule will then 5 compete for and inhibit the binding of a completely homologous molecule to the target molecule under various conditions of stringency, as taught in Wahl, G.M. and S.L. Berger (1987; Methods Enzymol. 152:399-407) and Kimmel, A.R. (1987; Methods Enzymol. 152:507-511).

"Stringency" refers to conditions in a hybridization reaction that favour the association of 10 very similar molecules over association of molecules that differ. High stringency hybridisation conditions are defined as overnight incubation at 42°C in a solution comprising 50% formamide, 5XSSC (150mM NaCl, 15mM trisodium citrate), 50mM sodium phosphate (pH7.6), 5x Denhardts solution, 10% dextran sulphate, and 20 microgram/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 15 0.1X SSC at approximately 65°C. Low stringency conditions involve the hybridisation reaction being carried out at 35°C (see Sambrook *et al.* [*supra*]). Preferably, the conditions used for hybridization are those of high stringency.

Preferred embodiments of this aspect of the invention are nucleic acid molecules that are at least 70% identical over their entire length to a nucleic acid molecule encoding the 20 INSP108 or INSP109 polypeptides and nucleic acid molecules that are substantially complementary to such nucleic acid molecules. Preferably, a nucleic acid molecule according to this aspect of the invention comprises a region that is at least 80% identical over its entire length to such coding sequences, or is a nucleic acid molecule that is complementary thereto. In this regard, nucleic acid molecules at least 90%, preferably at 25 least 95%, more preferably at least 98%, 99% or more identical over their entire length to the same are particularly preferred. Preferred embodiments in this respect are nucleic acid molecules that encode polypeptides which retain substantially the same biological function or activity as the INSP108 or INSP109 polypeptides.

The invention also provides a process for detecting a nucleic acid molecule of the 30 invention, comprising the steps of: (a) contacting a nucleic probe according to the invention with a biological sample under hybridizing conditions to form duplexes; and (b) detecting any such duplexes that are formed.

As discussed additionally below in connection with assays that may be utilised according to the invention, a nucleic acid molecule as described above may be used as a hybridization probe for RNA, cDNA or genomic DNA, in order to isolate full-length cDNAs and genomic clones encoding the INSP108 or INSP109 polypeptides and to isolate 5 cDNA and genomic clones of homologous or orthologous genes that have a high sequence similarity to the gene encoding this polypeptide.

In this regard, the following techniques, among others known in the art, may be utilised and are discussed below for purposes of illustration. Methods for DNA sequencing and analysis are well known and are generally available in the art and may, indeed, be used to 10 practice many of the embodiments of the invention discussed herein. Such methods may employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase (US Biochemical Corp, Cleveland, OH), Taq polymerase (Perkin Elmer), thermostable T7 polymerase (Amersham, Chicago, IL), or combinations of polymerases and proof-reading exonucleases such as those found in the ELONGASE Amplification System marketed by 15 Gibco/BRL (Gaithersburg, MD). Preferably, the sequencing process may be automated using machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno, NV), the Peltier and 377 DNA Sequencers (Perkin Elmer).

One method for isolating a nucleic acid molecule encoding a polypeptide with an 20 equivalent function to that of the INSP108 polypeptide is to probe a genomic or cDNA library with a natural or artificially-designed probe using standard procedures that are recognised in the art (see, for example, "Current Protocols in Molecular Biology", Ausubel *et al.* (eds). Greene Publishing Association and John Wiley Interscience, New York, 1989,1992). Probes comprising at least 15, preferably at least 30, and more preferably at 25 least 50, contiguous bases that correspond to, or are complementary to, nucleic acid sequences from the appropriate encoding gene (SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13 and SEQ ID NO:15), are particularly useful probes. Such probes may be labelled with an analytically-detectable reagent to facilitate their identification. Useful reagents include, but are not limited to, 30 radioisotopes, fluorescent dyes and enzymes that are capable of catalysing the formation of a detectable product. Using these probes, the ordinarily skilled artisan will be capable of isolating complementary copies of genomic DNA, cDNA or RNA polynucleotides encoding proteins of interest from human, mammalian or other animal sources and

screening such sources for related sequences, for example, for additional members of the family, type and/or subtype.

- In many cases, isolated cDNA sequences will be incomplete, in that the region encoding the polypeptide will be cut short, normally at the 5' end. Several methods are available to
- 5 obtain full length cDNAs, or to extend short cDNAs. Such sequences may be extended utilising a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, one method which may be employed is based on the method of Rapid Amplification of cDNA Ends (RACE; see, for example, Frohman *et al.*, PNAS USA 85, 8998-9002, 1988). Recent
- 10 modifications of this technique, exemplified by the MarathonTM technology (Clontech Laboratories Inc.), for example, have significantly simplified the search for longer cDNAs. A slightly different technique, termed "restriction-site" PCR, uses universal primers to retrieve unknown nucleic acid sequence adjacent a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). Inverse PCR may also be used to amplify or to extend
- 15 sequences using divergent primers based on a known region (Triglia, T. *et al.* (1988) Nucleic Acids Res. 16:8186). Another method which may be used is capture PCR which
- yeast artificial chromosome DNA (Lagerstrom, M. *et al.* (1991) PCR Methods Applic., 1, 111-119). Another method which may be used to retrieve unknown sequences is that of
- 20 Parker, J.D. *et al.* (1991); Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PromoterFinderTM libraries to walk genomic DNA (Clontech, Palo Alto, CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.
- When screening for full-length cDNAs, it is preferable to use libraries that have been size-
- 25 selected to include larger cDNAs. Also, random-primed libraries are preferable, in that they will contain more sequences that contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.
- 30 In one embodiment of the invention, the nucleic acid molecules of the present invention may be used for chromosome localisation. In this technique, a nucleic acid molecule is specifically targeted to, and can hybridize with, a particular location on an individual

human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important step in the confirmatory correlation of those sequences with the gene-associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be
5 correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationships between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes). This provides valuable information to investigators
10 searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localised by genetic linkage to a particular genomic region, any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleic acid molecule may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among
15 normal, carrier, or affected individuals.

The nucleic acid molecules of the present invention are also valuable for tissue polypeptide in tissues by detection of the mRNAs that encode them. These techniques include *in situ* hybridization techniques and nucleotide amplification techniques, such as
20 PCR. Results from these studies provide an indication of the normal functions of the polypeptide in the organism. In addition, comparative studies of the normal expression pattern of mRNAs with that of mRNAs encoded by a mutant gene provide valuable insights into the role of mutant polypeptides in disease. Such inappropriate expression may be of a temporal, spatial or quantitative nature.
25 Gene silencing approaches may also be undertaken to down-regulate endogenous expression of a gene encoding a polypeptide of the invention. RNA interference (RNAi) (Elbashir, SM *et al.*, Nature 2001, 411, 494-498) is one method of sequence specific post-transcriptional gene silencing that may be employed. Short dsRNA oligonucleotides are synthesised *in vitro* and introduced into a cell. The sequence specific binding of these
30 dsRNA oligonucleotides triggers the degradation of target mRNA, reducing or ablating target protein expression.

Efficacy of the gene silencing approaches assessed above may be assessed through the

measurement of polypeptide expression (for example, by Western blotting), and at the RNA level using TaqMan-based methodologies.

The vectors of the present invention comprise nucleic acid molecules of the invention and may be cloning or expression vectors. The host cells of the invention, which may be 5 transformed, transfected or transduced with the vectors of the invention may be prokaryotic or eukaryotic.

The polypeptides of the invention may be prepared in recombinant form by expression of their encoding nucleic acid molecules in vectors contained within a host cell. Such expression methods are well known to those of skill in the art and many are described in 10 detail by Sambrook *et al.* (*supra*) and Fernandez & Hoeffler (1998, eds. "Gene expression systems. Using nature for the art of expression". Academic Press, San Diego, London, Boston, New York, Sydney, Tokyo, Toronto).

Generally, any system or vector that is suitable to maintain, propagate or express nucleic acid molecules to produce a polypeptide in the required host may be used. The appropriate 15 nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as for example those described in Sambrook *et al.* (*supra*). Generally, the encoding gene can be placed under the control of a control element such as a promoter, ribosome binding site (for bacterial expression) and, optionally, an operator, so that the DNA sequence encoding the desired polypeptide is transcribed into 20 RNA in the transformed host cell.

Examples of suitable expression systems include, for example, chromosomal, episomal and virus-derived systems, including, for example, vectors derived from: bacterial plasmids, bacteriophage, transposons, yeast episomes, insertion elements, yeast chromosomal elements, viruses such as baculoviruses, papova viruses such as SV40, vaccinia viruses, 25 adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, or combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, including cosmids and phagemids. Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained and expressed in a plasmid. The vectors pCR4-TOPO-INSP108 (Figure 9), pDONR-INSP108-6HIS (Figure 13), 30 pEAK12d-INSP108-6HIS (Figure 14), pDEST12.2-INSP108-6HIS (Figure 15), pCR4-TOPO-INSP109 (Figure 19), pDONR-INSP109-6HIS (Figure 20), pEAK12d-INSP109-6HIS (Figure 21) and pDEST12.2-INSP109-6HIS (Figure 22), are preferred examples of

suitable vectors for use in accordance with the aspects of this invention relating to INSP108 and INSP109.

Particularly suitable expression systems include microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; 5 yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (for example, baculovirus); plant cell systems transformed with virus expression vectors (for example, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (for example, Ti or pBR322 plasmids); or animal cell systems. Cell-free translation systems can also be employed to produce the 10 polypeptides of the invention.

Introduction of nucleic acid molecules encoding a polypeptide of the present invention into host cells can be effected by methods described in many standard laboratory manuals, such as Davis *et al.*, *Basic Methods in Molecular Biology* (1986) and Sambrook *et al.*, (*supra*). Particularly suitable methods include calcium phosphate transfection, DEAE-dextran 15 mediated transfection, transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection (see ~~SAMBROOK ET AL., 1989, INVESTIGATING MOLECULAR BIOLOGY, PART 2, CHAPTER 10~~ Leinwald, 1998). In eukaryotic cells, expression systems may either be transient (for example, episomal) or permanent (chromosomal integration) according to the needs of the 20 system.

The encoding nucleic acid molecule may or may not include a sequence encoding a control sequence, such as a signal peptide or leader sequence, as desired, for example, for secretion of the translated polypeptide into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment. These signals may be 25 endogenous to the polypeptide or they may be heterologous signals. Leader sequences can be removed by the bacterial host in post-translational processing.

In addition to control sequences, it may be desirable to add regulatory sequences that allow for regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory sequences are those which cause the expression of a gene to be 30 increased or decreased in response to a chemical or physical stimulus, including the presence of a regulatory compound or to various temperature or metabolic conditions. Regulatory sequences are those non-translated regions of the vector, such as enhancers,

- promoters and 5' and 3' untranslated regions. These interact with host cellular proteins to carry out transcription and translation. Such regulatory sequences may vary in their strength and specificity. Depending on the vector system and host utilised, any number of suitable transcription and translation elements, including constitutive and inducible 5 promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript phagemid (Stratagene, LaJolla, CA) or pSportTM plasmid (Gibco BRL) and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (for example, heat shock, RUBISCO and storage protein genes) or 10 from plant viruses (for example, viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence, vectors based on SV40 or EBV may be used with an appropriate selectable marker.
- 15 An expression vector is constructed so that the particular nucleic acid coding sequence is located in the vector with the appropriate regulatory sequences, the positioning and the coding sequence is transcribed under the "control" of the regulatory sequences, i.e., RNA polymerase which binds to the DNA molecule at the control sequences transcribes 20 the coding sequence. In some cases it may be necessary to modify the sequence so that it may be attached to the control sequences with the appropriate orientation; i.e., to maintain the reading frame.
- The control sequences and other regulatory sequences may be ligated to the nucleic acid coding sequence prior to insertion into a vector. Alternatively, the coding sequence can be 25 cloned directly into an expression vector that already contains the control sequences and an appropriate restriction site.
- For long-term, high-yield production of a recombinant polypeptide, stable expression is preferred. For example, cell lines which stably express the polypeptide of interest may be transformed using expression vectors which may contain viral origins of replication and/or 30 endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the

selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells that successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

- 5 Mammalian cell lines available as hosts for expression are known in the art and include many immortalised cell lines available from the American Type Culture Collection (ATCC) including, but not limited to, Chinese hamster ovary (CHO), HeLa, baby hamster kidney (BHK), monkey kidney (COS), C127, 3T3, BHK, HEK 293, Bowes melanoma and human hepatocellular carcinoma (for example Hep G2) cells and a number of other cell
10 lines.

- In the baculovirus system, the materials for baculovirus/insect cell expression systems are commercially available in kit form from, *inter alia*, Invitrogen, San Diego CA (the "MaxBac" kit). These techniques are generally known to those skilled in the art and are described fully in Summers and Smith, Texas Agricultural Experiment Station Bulletin No.
15 1555 (1987). Particularly suitable host cells for use in this system include insect cells such as *Drosophila S2* and *Spodoptera Sf9* cells.

- ~~There are many plant cell culture and whole plant genetic expression systems known in the art.~~ Examples of suitable plant cellular genetic expression systems include those described in US 5,693,506; US 5,659,122; and US 5,608,143. Additional examples of genetic
20 expression in plant cell culture has been described by Zenk, *Phytochemistry* 30, 3861-3863 (1991).

- In particular, all plants from which protoplasts can be isolated and cultured to give whole regenerated plants can be utilised, so that whole plants are recovered which contain the transferred gene. Practically all plants can be regenerated from cultured cells or tissues,
25 including but not limited to all major species of sugar cane, sugar beet, cotton, fruit and other trees, legumes and vegetables.

Examples of particularly preferred bacterial host cells include *streptococci*, *staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells.

- Examples of particularly suitable host cells for fungal expression include yeast cells (for
30 example, *S. cerevisiae*) and *Aspergillus* cells.

Any number of selection systems are known in the art that may be used to recover

transformed cell lines. Examples include the herpes simplex virus thymidine kinase (Wigler, M. *et al.* (1977) *Cell* 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. *et al.* (1980) *Cell* 22:817-23) genes that can be employed in tk⁻ or aprt[±] cells, respectively.

Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for 5 selection; for example, dihydrofolate reductase (DHFR) that confers resistance to methotrexate (Wigler, M. *et al.* (1980) *Proc. Natl. Acad. Sci.* 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. *et al.* (1981) *J. Mol. Biol.* 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. Additional selectable genes have been 10 described, examples of which will be clear to those of skill in the art.

Although the presence or absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For example, if the relevant sequence is inserted within a marker gene sequence, transformed cells containing the appropriate sequences can be identified by the absence of marker gene 15 function. Alternatively, a marker gene can be placed in tandem with a sequence encoding a polypeptide of the invention under the control of a single promoter. Expression of the tandem gene as well.

Alternatively, host cells that contain a nucleic acid sequence encoding a polypeptide of the 20 invention and which express said polypeptide may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassays, for example, fluorescence activated cell sorting (FACS) or immunoassay techniques (such as the enzyme-linked immunosorbent assay [ELISA] and radioimmunoassay [RIA]), that include membrane, 25 solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein (see Hampton, R. *et al.* (1990) *Serological Methods, a Laboratory Manual*, APS Press, St Paul, MN) and Maddox, D.E. *et al.* (1983) *J. Exp. Med.*, 158, 1211-1216).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing 30 labelled hybridization or PCR probes for detecting sequences related to nucleic acid molecules encoding polypeptides of the present invention include oligolabelling, nick translation, end-labelling or PCR amplification using a labelled polynucleotide.

Alternatively, the sequences encoding the polypeptide of the invention may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesise RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labelled nucleotides. These 5 procedures may be conducted using a variety of commercially available kits (Pharmacia & Upjohn, (Kalamazoo, MI); Promega (Madison WI); and U.S. Biochemical Corp., Cleveland, OH).

Suitable reporter molecules or labels, which may be used for ease of detection, include radionuclides, enzymes and fluorescent, chemiluminescent or chromogenic agents as well 10 as substrates, cofactors, inhibitors, magnetic particles, and the like.

Nucleic acid molecules according to the present invention may also be used to create transgenic animals, particularly rodent animals. Such transgenic animals form a further aspect of the present invention. This may be done locally by modification of somatic cells, or by germ line therapy to incorporate heritable modifications. Such transgenic animals 15 may be particularly useful in the generation of animal models for drug molecules effective as modulators of the polypeptides of the present invention.

The polypeptide can be recovered and purified from recombinant host bacteria by well known methods including ammonium sulphate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, 20 hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. High performance liquid chromatography is particularly useful for purification. Well known techniques for refolding proteins may be employed to regenerate an active conformation when the polypeptide is denatured during isolation and or purification.

25 Specialised vector constructions may also be used to facilitate purification of proteins, as desired, by joining sequences encoding the polypeptides of the invention to a nucleotide sequence encoding a polypeptide domain that will facilitate purification of soluble proteins. Examples of such purification-facilitating domains include metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilised 30 metals, protein A domains that allow purification on immobilised immunoglobulin, and the domain utilised in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, WA). The inclusion of cleavable linker sequences such as those specific for Factor

- XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and the polypeptide of the invention may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing the polypeptide of the invention fused to several histidine residues preceding a thioredoxin or an enterokinase
- 5 cleavage site. The histidine residues facilitate purification by IMAC (immobilised metal ion affinity chromatography as described in Porath, J. *et al.* (1992), *Prot. Exp. Purif.* 3: 263-281) while the thioredoxin or enterokinase cleavage site provides a means for purifying the polypeptide from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D.J. *et al.* (1993; *DNA Cell Biol.* 12:441-453).
- 10 If the polypeptide is to be expressed for use in screening assays, generally it is preferred that it be produced at the surface of the host cell in which it is expressed. In this event, the host cells may be harvested prior to use in the screening assay, for example using techniques such as fluorescence activated cell sorting (FACS) or immunoaffinity techniques. If the polypeptide is secreted into the medium, the medium can be recovered in
- 15 order to recover and purify the expressed polypeptide. If polypeptide is produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

variety of drug screening techniques. Such compounds may activate (agonise) or inhibit (antagonise) the level of expression of the gene or the activity of the polypeptide of the

20 invention and form a further aspect of the present invention. Preferred compounds are effective to alter the expression of a natural gene which encodes a polypeptide of the first aspect of the invention or to regulate the activity of a polypeptide of the first aspect of the invention.

Agonist or antagonist compounds may be isolated from, for example, cells, cell-free preparations, chemical libraries or natural product mixtures. These agonists or antagonists may be natural or modified substrates, ligands, enzymes, receptors or structural or functional mimetics. For a suitable review of such screening techniques, see Coligan *et al.*, *Current Protocols in Immunology* 1(2):Chapter 5 (1991).

Compounds that are most likely to be good antagonists are molecules that bind to the

30 polypeptide of the invention without inducing the biological effects of the polypeptide upon binding to it. Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to the polypeptide of the invention and thereby

inhibit or extinguish its activity. In this fashion, binding of the polypeptide to normal cellular binding molecules may be inhibited, such that the normal biological activity of the polypeptide is prevented.

- The polypeptide of the invention that is employed in such a screening technique may be
- 5 free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. In general, such screening procedures may involve using appropriate cells or cell membranes that express the polypeptide that are contacted with a test compound to observe binding, or stimulation or inhibition of a functional response. The functional response of the cells contacted with the test compound is then compared with control cells that were
- 10 not contacted with the test compound. Such an assay may assess whether the test compound results in a signal generated by activation of the polypeptide, using an appropriate detection system. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist in the presence of the test compound is observed.
- 15 A preferred method for identifying an agonist or antagonist compound of a polypeptide of the present invention comprises:
- (a) contacting a cell expressing on the surface thereof the polypeptide with a second component capable of providing a detectable signal in response to the binding of a compound to the
- 20 polypeptide, with a compound to be screened under conditions to permit binding to the polypeptide; and
- (b) determining whether the compound binds to and activates or inhibits the polypeptide by measuring the level of a signal generated from the interaction of the compound with the polypeptide.
- 25 A further preferred method for identifying an agonist or antagonist of a polypeptide of the invention comprises:
- (a) contacting a cell expressing on the surface thereof the polypeptide, the polypeptide being associated with a second component capable of providing a detectable signal in response to the binding of a compound to the polypeptide, with a compound to be screened
- 30 under conditions to permit binding to the polypeptide; and
- (b) determining whether the compound binds to and activates or inhibits the polypeptide by

comparing the level of a signal generated from the interaction of the compound with the polypeptide with the level of a signal in the absence of the compound.

In further preferred embodiments, the general methods that are described above may further comprise conducting the identification of agonist or antagonist in the presence of 5 labelled or unlabelled ligand or receptor for the polypeptide.

In another embodiment of the method for identifying an agonist or antagonist of a polypeptide of the present invention comprises:

determining the inhibition of binding of a ligand or receptor to cells which have a polypeptide of the invention on the surface thereof, or to cell membranes containing such a 10 polypeptide, in the presence of a candidate compound under conditions to permit binding to the polypeptide, and determining the amount of ligand or receptor bound to the polypeptide. A compound capable of causing reduction of binding of a ligand or receptor is considered to be an agonist or antagonist. Preferably the ligand is labelled.

More particularly, a method of screening for a polypeptide antagonist or agonist compound 15 comprises the steps of:

according to the invention on the cell surface, or a cell membrane containing a polypeptide of the invention,

(b) measuring the amount of labelled ligand or receptor bound to the whole cell or the cell 20 membrane;

(c) adding a candidate compound to a mixture of labelled ligand or receptor and the whole cell or the cell membrane of step (a) and allowing the mixture to attain equilibrium;

(d) measuring the amount of labelled ligand or receptor bound to the whole cell or the cell membrane after step (c); and

25 (e) comparing the difference in the labelled ligand or receptor bound in step (b) and (d), such that the compound which causes the reduction in binding in step (d) is considered to be an agonist or antagonist.

The INSP108 and INSP109 polypeptides may also be found to modulate immune system cell proliferation and differentiation in a dose-dependent manner in the above-described 30 assays. Thus, the "functional equivalents" of the INSP108 and INSP109 polypeptides

include polypeptides that exhibit any of the same growth and differentiation regulating activities in the above-described assays in a dose-dependent manner. Although the degree of dose-dependent activity need not be identical to that of the INSP108 or INSP109 polypeptides, preferably the "functional equivalents" will exhibit substantially similar 5 dose-dependence in a given activity assay compared to the INSP108 and INSP109 polypeptides.

- In certain of the embodiments described above, simple binding assays may be used, in which the adherence of a test compound to a surface bearing the polypeptide is detected by means of a label directly or indirectly associated with the test compound or in an assay 10 involving competition with a labelled competitor. In another embodiment, competitive drug screening assays may be used, in which neutralising antibodies that are capable of binding the polypeptide specifically compete with a test compound for binding. In this manner, the antibodies can be used to detect the presence of any test compound that possesses specific binding affinity for the polypeptide.
- 15 Assays may also be designed to detect the effect of added test compounds on the production of mRNA encoding the polypeptide in cells. For example, an ELISA may be monoclonal or polyclonal antibodies by standard methods known in the art, and this can be used to search for compounds that may inhibit or enhance the production of the 20 polypeptide from suitably manipulated cells or tissues. The formation of binding complexes between the polypeptide and the compound being tested may then be measured. A beta defensin antimicrobial assay is described by Nizet *et al.* (*Nature* 2001, 414:454-457). A theta defensin antimicrobial and antiviral assay is described by Cole *et al.* (*Proc. Natl. Acad. Sci.* 2002, 99(4):1813-1818).
- 25 Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the polypeptide of interest (see International patent application WO84/03564). In this method, large numbers of different small test compounds are synthesised on a solid substrate, which may then be reacted with the polypeptide of the invention and washed. One way of immobilising the polypeptide is 30 to use non-neutralising antibodies. Bound polypeptide may then be detected using methods that are well known in the art. Purified polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques.

The polypeptide of the invention may be used to identify membrane-bound or soluble receptors, through standard receptor binding techniques that are known in the art, such as ligand binding and crosslinking assays in which the polypeptide is labelled with a radioactive isotope, is chemically modified, or is fused to a peptide sequence that

5 facilitates its detection or purification, and incubated with a source of the putative receptor (for example, a composition of cells, cell membranes, cell supernatants, tissue extracts, or bodily fluids). The efficacy of binding may be measured using biophysical techniques such as surface plasmon resonance and spectroscopy. Binding assays may be used for the purification and cloning of the receptor, but may also identify agonists and antagonists of

10 the polypeptide, that compete with the binding of the polypeptide to its receptor. Standard methods for conducting screening assays are well understood in the art.

The invention also includes a screening kit useful in the methods for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, that are described above.

The invention includes the agonists, antagonists, ligands, receptors, substrates and

15 enzymes, and other compounds which modulate the activity or antigenicity of the polypeptide of the invention discovered by the methods that are described above.

~~THE INVENTION ALSO PROVIDES PHARMACEUTICAL COMPOSITIONS OF THE POLYPEPTIDE, NUCLEIC ACID, LIGAND OR COMPOUND OF THE INVENTION IN COMBINATION WITH A SUITABLE PHARMACEUTICAL CARRIER.~~

nucleic acid, ligand or compound of the invention in combination with a suitable pharmaceutical carrier. These compositions may be suitable as therapeutic or diagnostic

20 reagents, as vaccines, or as other immunogenic compositions, as outlined in detail below.

According to the terminology used herein, a composition containing a polypeptide, nucleic acid, ligand or compound [X] is "substantially free of" impurities [herein, Y] when at least 85% by weight of the total X+Y in the composition is X. Preferably, X comprises at least about 90% by weight of the total of X+Y in the composition, more preferably at least about

25 95%, 98% or even 99% by weight.

The pharmaceutical compositions should preferably comprise a therapeutically effective amount of the polypeptide, nucleic acid molecule, ligand, or compound of the invention. The term "therapeutically effective amount" as used herein refers to an amount of a therapeutic agent needed to treat, ameliorate, or prevent a targeted disease or condition, or

30 to exhibit a detectable therapeutic or preventative effect. For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, for example, of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The

animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

The precise effective amount for a human subject will depend upon the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. This amount can be determined by routine experimentation and is within the judgement of the clinician. Generally, an effective dose will be from 0.01 mg/kg to 50 mg/kg, preferably 0.05 mg/kg to 10 mg/kg. Compositions may be administered individually to a patient or may be administered in combination with other agents, drugs or hormones.

A pharmaceutical composition may also contain a pharmaceutically acceptable carrier, for administration of a therapeutic agent. Such carriers include antibodies and other polypeptides, genes and other therapeutic agents such as liposomes, provided that the carrier does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity.

polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles.

- 20 Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulphates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable carriers is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991).
- 25 Pharmaceutically acceptable carriers in therapeutic compositions may additionally contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such compositions. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like,
- 30 for ingestion by the patient.

Once formulated, the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals; in particular, human subjects can be

treated.

The pharmaceutical compositions utilised in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal or transcutaneous applications (for example, see WO98/20734), subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal or rectal means. Gene guns or hyposprays may also be used to administer the pharmaceutical compositions of the invention. Typically, the therapeutic compositions may be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared.

Direct delivery of the compositions will generally be accomplished by injection, subcutaneously, intraperitoneally, intravenously or intramuscularly, or delivered to the interstitial space of a tissue. The compositions can also be administered into a lesion. Dosage treatment may be a single dose schedule or a multiple dose schedule.

If the activity of the polypeptide of the invention is in excess in a particular disease state, several approaches are available. One approach comprises administering to a subject an ~~immunotherapy compound comprising a polypeptide, such as~~ acceptable carrier in an amount effective to inhibit the function of the polypeptide, such as by blocking the binding of ligands, substrates, enzymes, receptors, or by inhibiting a second signal, and thereby alleviating the abnormal condition. Preferably, such antagonists are antibodies. Most preferably, such antibodies are chimeric and/or humanised to minimise their immunogenicity, as described previously.

In another approach, soluble forms of the polypeptide that retain binding affinity for the ligand, substrate, enzyme, receptor, in question, may be administered. Typically, the polypeptide may be administered in the form of fragments that retain the relevant portions.

In an alternative approach, expression of the gene encoding the polypeptide can be inhibited using expression blocking techniques, such as the use of antisense nucleic acid molecules (as described above), either internally generated or separately administered. Modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5' or regulatory regions (signal sequence, promoters, enhancers and introns) of the gene encoding the polypeptide. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple

helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules.

Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J.E. *et al.* (1994) In: Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches,

- 5 Futura Publishing Co., Mt. Kisco, NY). The complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes. Such oligonucleotides may be administered or may be generated *in situ* from expression *in vivo*.

In addition, expression of the polypeptide of the invention may be prevented by using 10 ribozymes specific to its encoding mRNA sequence. Ribozymes are catalytically active

RNAs that can be natural or synthetic (see for example Usman, N, *et al.*, Curr. Opin. Struct. Biol (1996) 6(4), 527-33). Synthetic ribozymes can be designed to specifically cleave mRNAs at selected positions thereby preventing translation of the mRNAs into functional polypeptide. Ribozymes may be synthesised with a natural ribose phosphate

- 15 backbone and natural bases, as normally found in RNA molecules. Alternatively the ribozymes may be synthesised with non-natural backbones, for example, 2'-O-methyl

bases.

RNA molecules may be modified to increase intracellular stability and half-life. Possible 20 modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent

in the production of PNAs and can be extended in all of these molecules by the inclusion of non-traditional bases such as inosine, queosine and butosine, as well as acetyl-, methyl-, thio- and similarly modified forms of adenine, cytidine, guanine, thymine and uridine which are not as easily recognised by endogenous endonucleases.

For treating abnormal conditions related to an under-expression of the polypeptide of the invention and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound that activates 30 the polypeptide, i.e., an agonist as described above, to alleviate the abnormal condition. Alternatively, a therapeutic amount of the polypeptide in combination with a suitable pharmaceutical carrier may be administered to restore the relevant physiological balance of

polypeptide.

Gene therapy may be employed to effect the endogenous production of the polypeptide by the relevant cells in the subject. Gene therapy is used to treat permanently the inappropriate production of the polypeptide by replacing a defective gene with a corrected therapeutic gene.

Gene therapy of the present invention can occur *in vivo* or *ex vivo*. *Ex vivo* gene therapy requires the isolation and purification of patient cells, the introduction of a therapeutic gene and introduction of the genetically altered cells back into the patient. In contrast, *in vivo* gene therapy does not require isolation and purification of a patient's cells.

- 10 The therapeutic gene is typically "packaged" for administration to a patient. Gene delivery vehicles may be non-viral, such as liposomes, or replication-deficient viruses, such as adenovirus as described by Berkner, K.L., in Curr. Top. Microbiol. Immunol., 158, 39-66 (1992) or adeno-associated virus (AAV) vectors as described by Muzyczka, N., in Curr. Top. Microbiol. Immunol., 158, 97-129 (1992) and U.S. Patent No. 5,252,479. For example, a nucleic acid molecule encoding a polypeptide of the invention may be engineered for expression in a replication-defective retroviral vector. This expression
- 15 ~~vector may then be inserted into a packaging cell line, such as~~
retroviral plasmid vector containing RNA encoding the polypeptide, such that the packaging cell now produces infectious viral particles containing the gene of interest.
- 20 These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the polypeptide *in vivo* (see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics (1996), T Strachan and A P Read, BIOS Scientific Publishers Ltd).

Another approach is the administration of "naked DNA" in which the therapeutic gene is directly injected into the bloodstream or muscle tissue.

In situations in which the polypeptides or nucleic acid molecules of the invention are disease-causing agents, the invention provides that they can be used in vaccines to raise antibodies against the disease causing agent.

Vaccines according to the invention may either be prophylactic (*i.e.* to prevent infection) or therapeutic (*i.e.* to treat disease after infection). Such vaccines comprise immunising antigen(s), immunogen(s), polypeptide(s), protein(s) or nucleic acid, usually in

combination with pharmaceutically-acceptable carriers as described above, which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Additionally, these carriers may function as immunostimulating agents ("adjuvants"). Furthermore, the antigen or immunogen may be conjugated to a 5 bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, *H. pylori*, and other pathogens.

Since polypeptides may be broken down in the stomach, vaccines comprising polypeptides are preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration 10 include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient, and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents.

The vaccine formulations of the invention may be presented in unit-dose or multi-dose 15 containers. For example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use.

determined by routine experimentation.

Genetic delivery of antibodies that bind to polypeptides according to the invention may 20 also be effected, for example, as described in International patent application WO98/55607.

The technology referred to as jet injection (see, for example, www.powderject.com) may also be useful in the formulation of vaccine compositions.

A number of suitable methods for vaccination and vaccine delivery systems are described 25 in International patent application WO00/29428.

This invention also relates to the use of nucleic acid molecules according to the present invention as diagnostic reagents. Detection of a mutated form of the gene characterised by the nucleic acid molecules of the invention which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or 30 susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may

be detected at the DNA level by a variety of techniques.

Nucleic acid molecules for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR, ligase chain reaction (LCR), strand displacement amplification (SDA), or other amplification techniques (see Saiki *et al.*, *Nature*, 324, 163-166 (1986); Bej, *et al.*, *Crit. Rev. Biochem. Molec. Biol.*, 26, 301-334 (1991); Birkenmeyer *et al.*, *J. Virol. Meth.*, 35, 117-126 (1991); Van Brunt, J., *Bio/Technology*, 8, 291-294 (1990)) prior to analysis.

In one embodiment, this aspect of the invention provides a method of diagnosing a disease 10 in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to the invention and comparing said level of expression to a control level, wherein a level that is different to said control level is indicative of disease. The method may comprise the steps of:

- a)contacting a sample of tissue from the patient with a nucleic acid probe under stringent 15 conditions that allow the formation of a hybrid complex between a nucleic acid molecule of the invention and the probe;
- b)contacting a control sample with said probe under the same conditions used in step a);
- c)and detecting the presence of hybrid complexes in said samples;

wherein detection of levels of the hybrid complex in the patient sample that differ from 20 levels of the hybrid complex in the control sample is indicative of disease.

A further aspect of the invention comprises a diagnostic method comprising the steps of:

- a)obtaining a tissue sample from a patient being tested for disease;
- b)isolating a nucleic acid molecule according to the invention from said tissue sample; and
- c)diagnosing the patient for disease by detecting the presence of a mutation in the nucleic 25 acid molecule which is associated with disease.

To aid the detection of nucleic acid molecules in the above-described methods, an amplification step, for example using PCR, may be included.

Deletions and insertions can be detected by a change in the size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing 30 amplified DNA to labelled RNA of the invention or alternatively, labelled antisense DNA

sequences of the invention. Perfectly-matched sequences can be distinguished from mismatched duplexes by RNase digestion or by assessing differences in melting temperatures. The presence or absence of the mutation in the patient may be detected by contacting DNA with a nucleic acid probe that hybridises to the DNA under stringent conditions to form a hybrid double-stranded molecule, the hybrid double-stranded molecule having an unhybridised portion of the nucleic acid probe strand at any portion corresponding to a mutation associated with disease; and detecting the presence or absence of an unhybridised portion of the probe strand as an indication of the presence or absence of a disease-associated mutation in the corresponding portion of the DNA strand.

10 Such diagnostics are particularly useful for prenatal and even neonatal testing.

Point mutations and other sequence differences between the reference gene and "mutant" genes can be identified by other well-known techniques, such as direct DNA sequencing or single-strand conformational polymorphism, (see Orita *et al.*, Genomics, 5, 874-879 (1989)). For example, a sequencing primer may be used with double-stranded PCR product 15 or a single-stranded template molecule generated by a modified PCR. The sequence determination is performed by conventional procedures with radiolabelled nucleotides or

also be used as probes to detect specific DNA segments. The sensitivity of this method is greatly enhanced when combined with PCR. Further, point mutations and other sequence 20 variations, such as polymorphisms, can be detected as described above, for example, through the use of allele-specific oligonucleotides for PCR amplification of sequences that differ by single nucleotides.

DNA sequence differences may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA 25 sequencing (for example, Myers *et al.*, Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc. Natl. Acad. Sci. USA (1985) 85: 4397-4401).

In addition to conventional gel electrophoresis and DNA sequencing, mutations such as 30 microdeletions, aneuploidies, translocations, inversions, can also be detected by *in situ* analysis (see, for example, Keller *et al.*, DNA Probes, 2nd Ed., Stockton Press, New York, N.Y., USA (1993)), that is, DNA or RNA sequences in cells can be analysed for mutations

without need for their isolation and/or immobilisation onto a membrane. Fluorescence *in situ* hybridization (FISH) is presently the most commonly applied method and numerous reviews of FISH have appeared (see, for example, Trachuck *et al.*, Science, 250, 559-562 (1990), and Trask *et al.*, Trends, Genet., 7, 149-154 (1991)).

- 5 In another embodiment of the invention, an array of oligonucleotide probes comprising a nucleic acid molecule according to the invention can be constructed to conduct efficient screening of genetic variants, mutations and polymorphisms. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M.Chee *et al.*, Science (1996), Vol 274, pp 610-613).

In one embodiment, the array is prepared and used according to the methods described in PCT application WO95/11995 (Chee *et al.*; Lockhart, D. J. *et al.* (1996) Nat. Biotech. 14: 1675-1680); and Schena, M. *et al.* (1996) Proc. Natl. Acad. Sci. 93: 10614-10619). Oligonucleotide pairs may range from two to over one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any

the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/25116 (Baldeschweiler *et al.*). In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536 or 6144 oligonucleotides, or any other number between two and over one million which lends itself to the efficient use of commercially-available instrumentation.

In addition to the methods discussed above, diseases may be diagnosed by methods comprising determining, from a sample derived from a subject, an abnormally decreased or increased level of polypeptide or mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for

instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods.

- Assay techniques that can be used to determine levels of a polypeptide of the present invention in a sample derived from a host are well-known to those of skill in the art and are 5 discussed in some detail above (including radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays). This aspect of the invention provides a diagnostic method which comprises the steps of: (a) contacting a ligand as described above with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.
- 10 Protocols such as ELISA (as previously described), RIA, and FACS for measuring polypeptide levels may additionally provide a basis for diagnosing altered or abnormal levels of polypeptide expression. Normal or standard values for polypeptide expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably humans, with antibody to the polypeptide under conditions suitable for 15 complex formation. The amount of standard complex formation may be quantified by various methods, such as by photometric means.

~~ANTIBODIES WHICH SPECIFICALLY REACT WITH A POLYPEPTIDE OR THE ANALOGUE THEREOF~~

diagnosis of conditions or diseases characterised by expression of the polypeptide, or in assays to monitor patients being treated with the polypeptides, nucleic acid molecules, 20 ligands and other compounds of the invention. Antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for the polypeptide include methods that utilise the antibody and a label to detect the polypeptide in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labelled by joining them, either covalently 25 or non-covalently, with a reporter molecule. A wide variety of reporter molecules known in the art may be used, several of which are described above.

Quantities of polypeptide expressed in subject, control and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease. Diagnostic assays may be used to 30 distinguish between absence, presence, and excess expression of polypeptide and to monitor regulation of polypeptide levels during therapeutic intervention. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal

studies, in clinical trials or in monitoring the treatment of an individual patient.

A diagnostic kit of the present invention may comprise:

- (a) a nucleic acid molecule of the present invention;
- (b) a polypeptide of the present invention; or
- 5 (c) a ligand of the present invention.

In one aspect of the invention, a diagnostic kit may comprise a first container containing a nucleic acid probe that hybridises under stringent conditions with a nucleic acid molecule according to the invention; a second container containing primers useful for amplifying the nucleic acid molecule; and instructions for using the probe and primers for facilitating the 10 diagnosis of disease. The kit may further comprise a third container holding an agent for digesting unhybridised RNA.

In an alternative aspect of the invention, a diagnostic kit may comprise an array of nucleic acid molecules, at least one of which may be a nucleic acid molecule according to the invention.

15 To detect polypeptide according to the invention a diagnostic kit may comprise one or more antibodies that bind to a polypeptide according to the invention, and a reagent useful for the detection of a binding reaction between the antibody and the polypeptide.

Such kits will be of use in diagnosing a disease or susceptibility to disease in which members of the defensin family are implicated. Such diseases may include cell 20 proliferative disorders, including neoplasm, melanoma, lung, colorectal, breast, pancreas, head and neck and other solid tumours; myeloproliferative disorders, such as leukemia, non-Hodgkin lymphoma, leukopenia, thrombocytopenia, angiogenesis disorder, Kaposi's sarcoma; autoimmune/inflammatory disorders, including allergy, inflammatory bowel disease, arthritis, psoriasis and respiratory tract inflammation, asthma, and organ transplant 25 rejection; cardiovascular disorders, including hypertension, oedema, angina, atherosclerosis, thrombosis, sepsis, shock, reperfusion injury, and ischemia; neurological disorders including central nervous system disease, Alzheimer's disease, brain injury, amyotrophic lateral sclerosis, and pain; developmental disorders; metabolic disorders including diabetes mellitus, osteoporosis, and obesity, AIDS and renal disease; infections 30 including viral infection, bacterial infection, fungal infection and parasitic infection and other pathological conditions. Preferably, the diseases are those in which members of the

defensin family are implicated, such as sublethal endotoxaemia, septic shock, microbial infection of the amniotic cavity, Jarish-Herxheimer reaction of relapsing fever, infectious diseases of the central nervous system, acute pancreatitis, ulcerative colitis, empyaema, haemolytic uraemic syndrome, meningococcal disease, gastric infection, pertussis,
5 peritonitis, psoriasis, rheumatoid arthritis, sepsis, asthma, HIV, AIDS and glomerulonephritis.

Various aspects and embodiments of the present invention will now be described in more detail by way of example, with particular reference to the INSP108 and INSP109 polypeptides.

10 It will be appreciated that modification of detail may be made without departing from the scope of the invention.

Brief description of the Figures

Figure 1: BLAST result against NCBI non-redundant database using SEQ ID NO: 6 (the
15 INSP108 polypeptide)

defensin beta 123 (*Homo sapiens*)

Figure 3: Sig P cleavage site prediction for INSP108

Figure 4: BLAST result against NCBI non-redundant database using SEQ ID NO: 14 (the
20 INSP109 polypeptide)

Figure 5: Alignment between INSP109 polypeptide sequence (SEQ ID NO:14) and defensin beta 4 (*Mus musculus*)

Figure 6: Sig P cleavage site prediction for INSP109

Figure 7: Predicted nucleotide sequence of INSP108 with translation

25 **Figure 8:** Nucleotide sequence with translation of INSP108 PCR product cloned using primers INSP108-CP1 and INSP108-CP2

Figure 9: Map of pCR4-TOPO-INSP108

Figure 10: Map of pDONR 221

Figure 11: Map of expression vector pEAK12d

Figure 12: Map of expression vector pDEST12.2

Figure 13: Map of pDONR221-INSPI08-6HIS

Figure 14: Map of pEAK12d-INSPI08-6HIS

Figure 15: Map of pDEST12.2-INSPI08-6HIS

5 **Figure 16:** Predicted nucleotide sequence of INSPI09 with translation

Figure 17: INSPI09 coding exon organization in genomic DNA and position of PCR primers

Figure 18: Nucleotide sequence and translation of cloned INSPI09 ORF

Figure 19: Map of pCR4-TOPO-INSPI09

10 **Figure 20:** Map of pDONR-INSPI09-6HIS

Figure 21: Map of pEAK12d-INSPI09-6HIS

Figure 22: Map of pDEST12.2-INSPI09-6HIS

15 **Example 1: INSPI08**

The INSPI08 polypeptide sequence, shown in SEQ ID NO:6, was used as a BLAST query against the NCBI non-redundant sequence database. The top hit is to a *Homo sapiens* gene annotated as a defensin (Figure 1). INSPI08 aligns to this sequence with a significant E-value ($4e^{-6}$) (Figure 2), thus indicating a high degree of confidence in the prediction.

20 **Example 2: INSPI08 signal sequence**

Figure 3 show that INSPI08 is predicted to possess a signal peptide at the start of the protein. As the SigP data in Figure 3 clearly shows, the signal peptide cleavage site is thought to be between residues 24 and 25 of the INSPI08 polypeptide sequence (Nielsen, H. *et al.* 1997, Protein Engineering, 10, 1-6; Nielsen, H., and Krogh, A.: Prediction of 25 signal peptides and signal anchors by a hidden Markov model. In Proceedings of the Sixth International Conference on Intelligent Systems for Molecular Biology (ISMB 6), AAAI Press, Menlo Park, California, pp. 122-130 (1998)).

Example 3: INSPI09

The INSP109 polypeptide sequence, shown in SEQ ID NO:14, was used as a BLAST query against the NCBI non-redundant sequence database. The top hit is to a *Mus musculus* gene prediction that is unannotated, and the second hit was *Mus musculus* defensin beta 4 (NP_062702.1) (Figure 4). Figure 5 shows the INSP109 polypeptide 5 aligned with the *Mus musculus* defensin beta 4.

Example 4: INSP109 signal sequence

Figure 6 shows that INSP109 is predicted to possess a signal peptide at the start of the protein. As the SigP data in Figure 6 clearly shows, the signal peptide cleavage site is thought to be between residues 21 and 22 of the INSP109 polypeptide sequence (Nielsen,

- 10 H. et al. 1997, Protein Engineering, 10, 1-6; Nielsen, H., and Krogh, A.: Prediction of signal peptides and signal anchors by a hidden Markov model. In Proceedings of the Sixth International Conference on Intelligent Systems for Molecular Biology (ISMB 6), AAAI Press, Menlo Park, California, pp. 122-130 (1998)).

Example 5: Cloning of INSP108

15 1.1 Preparation of human cDNA templates

(Clontech, Stratagene, Ambion, Biochain Institute and in-house preparations) using Superscript II RNase H⁻ Reverse Transcriptase (Invitrogen) according to the manufacturer's protocol. Oligo (dT)₁₅ primer (1μl at 500μg/ml) (Promega), 2μg human 20 total RNA, 1μl 10mM dNTP mix (10mM each of dATP, dGTP, dCTP and dTTP at neutral pH) and sterile distilled water to a final volume of 12μl were combined in a 1.5ml Eppendorf tube, heated to 65°C for 5 min and then chilled on ice. The contents were collected by brief centrifugation and 4μl of 5X First-Strand Buffer, 2μl 0.1 M DTT, and 1μl RnaseOUT Recombinant Ribonuclease Inhibitor (40 units/μl, Invitrogen) were added. 25 The contents of the tube were mixed gently and incubated at 42°C for 2 min; then 1μl (200 units) of SuperScript II enzyme was added and mixed gently by pipetting. The mixture was incubated at 42°C for 50 min and then inactivated by heating at 70°C for 15 min. To remove RNA complementary to the cDNA, 1μl (2 units) of *E. coli* RNase H (Invitrogen) was added and the reaction mixture incubated at 37°C for 20 min. The final 21μl reaction 30 mix was diluted by adding 179μl sterile water to give a total volume of 200μl. Human cDNA samples used as templates for the amplification of INSP108 were derived from brain, kidney, liver, lung, placenta, skeletal muscle, small intestine, spleen, thyroid, colon,

testis, skin, pancreas, pituitary gland, salivary gland, adrenal gland, eye, and a mixture of cancer cell line samples (Universal Reference RNA sample, Stratagene).

1.2 Gene specific cloning primers for PCR

A pair of PCR primers having a length of between 18 and 25 bases were designed for 5 amplifying the complete coding sequence of the virtual cDNA using Primer Designer Software (Scientific & Educational Software, PO Box 72045, Durham, NC 27722-2045, USA). PCR primers were optimized to have a Tm close to $55 \pm 10^{\circ}\text{C}$ and a GC content of 40-60%. Primers were selected which had high selectivity for the target sequence (INSP108) with little or no none specific priming.

10 1.3 PCR amplification of INSP108 from a variety of human cDNA templates

Gene-specific cloning primers (INSP108-CP1 and INSP108-CP2, Figure 7, Figure 8 and Table 1) were designed to amplify a cDNA fragment of 245bp covering the entire 231bp coding predicted sequence of the INSP108. Analysis of the scientific literature suggested that beta-defensin proteins should be expressed on mucosal surfaces and by secretory 15 organs. The gene-specific cloning primers INSP108-CP1 and INSP108-CP2 were therefore

used to amplify cDNA - samples listed in Section 1.1 as the PCR template. The PCR reactions were performed in a final volume of 50 μl containing 1X Platinum® *Taq* High Fidelity PCR buffer, 2mM MgSO₄, 200 μM dNTPs, 0.2 μM of each cloning primer, 2.5 units of Platinum® *Taq* DNA High Fidelity (Invitrogen) DNA polymerase and 100ng of 20 human cDNA template using an MJ Research DNA Engine, programmed as follows: 94°C, 2 min; 40 cycles of 94°C, 30 sec, 55°C, 30 sec, 68°C, 30 sec, followed by 1 cycle at 68°C for 7 min and a holding cycle at 4°C.

A 5 μl aliquot of each amplification product was visualized on a 0.8% agarose gel in 1 X TAE buffer (Invitrogen) and a single PCR product was seen migrating at approximately 25 the predicted molecular mass in the sample corresponding to the testis cDNA. The remaining PCR product from the testis amplification was electrophoresed on a second 0.8% agarose gel and purified using the Qiagen MinElute DNA Purification System (Qiagen). The PCR product was eluted in 10 μl of EB buffer (10mM Tris.Cl, pH 8.5) and subcloned directly.

1.4 Subcloning of PCR Products

The PCR product was subcloned into the topoisomerase I modified cloning vector (pCR4-TOPO) using the TA cloning kit purchased from the Invitrogen Corporation using the conditions specified by the manufacturer. Briefly, 4 μ l of gel purified PCR product from
5 the human testis cDNA amplification was incubated for 15 min at room temperature with 1 μ l of TOPO vector and 1 μ l salt solution. The reaction mixture was then transformed into *E. coli* strain TOP10 (Invitrogen) as follows: a 50 μ l aliquot of One Shot TOP10 cells was thawed on ice and 2 μ l of TOPO reaction was added. The mixture was incubated for 15 min on ice and then heat shocked by incubation at 42°C for exactly 30s. Samples were returned
10 to ice and 250 μ l of warm (room temperature) SOC media was added. Samples were incubated with shaking (220 rpm) for 1h at 37°C. The transformation mixture was then plated on L-broth (LB) plates containing ampicillin (100 μ g/ml) and incubated overnight at 37°C.

1.5 Colony PCR

15 Colonies were inoculated into 50 μ l sterile water using a sterile toothpick. A 10 μ l aliquot of the inoculum was then subjected to PCR in a total reaction volume of 20 μ l containing 1X of AmpliTaq™ (Perkin Elmer) using an MJ Research DNA Engine. The cycling conditions were as follows: 94°C, 2 min; 30 cycles of 94°C, 30 sec, 48°C, 30 sec and 72°C
20 for 1 min. Samples were maintained at 4°C (holding cycle) before further analysis.

PCR reaction products were analyzed on 1% agarose gels in 1 X TAE buffer. Colonies which gave the expected PCR product size (245bp cDNA + 105bp due to the multiple cloning site or MCS) were grown up overnight at 37°C in 5ml L-Broth (LB) containing ampicillin (100 μ g /ml), with shaking at 220 rpm.

25 1.6 Plasmid DNA preparation and sequencing

Miniprep plasmid DNA was prepared from the 5 ml culture using a Qiaprep Turbo 9600 robotic system (Qiagen) or Wizard Plus SV Minipreps kit (Promega cat. no. 1460) according to the manufacturer's instructions. Plasmid DNA was eluted in 100 μ l of sterile water. The DNA concentration was measured using an Eppendorf BO photometer. Plasmid
30 DNA (200-500ng) was subjected to DNA sequencing with the T7 primer and T3 primer using the BigDyeTerminator system (Applied Biosystems cat. no. 4390246) according to

the manufacturer's instructions. The primer sequences are shown in Table 1. Sequencing reactions were purified using Dye-Ex columns (Qiagen) or Montage SEQ 96 cleanup plates (Millipore cat. no. LSKS09624) then analyzed on an Applied Biosystems 3700 sequencer.

- 5 Sequence analysis identified a clone containing a 100% match to the predicted INSP108 sequence. The sequence of the cloned cDNA fragment is shown in Figure 8. The plasmid map of the cloned PCR product (pCR4-TOPO-INSP108) (plasmid ID.13982) is shown in Figure 9.

2. Construction of a plasmid for the expression of INSP108 in HEK293/EBNA cells.

- 10 A pCR4-TOPO clone containing the full coding sequence (ORF) of INSP108 identified by DNA sequencing (pCR4-TOPO-INSP108, plasmid ID.13982) (figure 9) was then used to subclone the insert into the mammalian cell expression vectors pEAK12d (figure 11) and pDEST12.2 (figure 12) using the GatewayTM cloning methodology (Invitrogen).

- 2.1 Generation of Gateway compatible INSP108 ORF fused to an in frame 6HIS tag
15 sequence.

generates the ORF of INSP108 flanked at the 5' end by an attB1 recombination site and Kozak sequence, and flanked at the 3' end by a sequence encoding an in frame 6 histidine (6HIS) tag, a stop codon and the attB2 recombination site (Gateway compatible cDNA).

- 20 The first PCR reaction (in a final volume of 50μl) contains: 1.5μl of pCR4-TOPO-INSP108 (plasmid ID 13982), 1.5μl dNTPs (10mM), 5μl of 10X Pfx polymerase buffer, 1μl MgSO₄ (50mM), 0.5μl each of gene specific primer (100μM) (INSP108-EX1 and INSP0108-EX2), 2.5μl 10X EnhancerTM solution (Invitrogen) and 1μl Platinum Pfx DNA polymerase (Invitrogen). The PCR reaction was performed using an initial denaturing step
25 of 95°C for 2 min, followed by 15 cycles of 94°C for 15s; 55°C for 30s and 68°C for 2 min 30 sec; and a holding cycle of 4°C. The amplification products were purified directly from the PCR mixture using the Wizard PCR Preps DNA Purification System (Promega) and recovered in 50μl sterile water according to the manufacturer's instructions.

- The second PCR reaction (in a final volume of 50μl) contained 10μl purified PCR 1
30 product, 1.5μl dNTPs (10mM), 5μl of 10X Pfx polymerase buffer, 1μl MgSO₄ (50mM), 0.5μl of each Gateway conversion primer (100μM) (GCP forward and GCP reverse) and

0.5 μ l of Platinum Pfx DNA polymerase. The conditions for the 2nd PCR reaction were: 95°C for 1 min; 4 cycles of 94°C, 15 sec; 50°C, 30 sec and 68°C for 2 min 30sec; 19 cycles of 94°C, 15 sec; 55°C, 30 sec and 68°C, 2 min 30 sec; followed by a holding cycle of 4°C. PCR products were gel purified using the Wizard PCR prep DNA purification system 5 (Promega) according to the manufacturer's instructions.

2.2 Subcloning of Gateway compatible INSP108 ORF into Gateway entry vector pDONR221 and expression vectors pEAK12d and pDEST12.2

The second stage of the Gateway cloning process involves subcloning of the Gateway modified PCR product into the Gateway entry vector pDONR221 (Invitrogen, figure 10) as 10 follows: 5 μ l of purified product from PCR2 were incubated with 1 μ l pDONR221 vector (0.15 μ g/ μ l), 2 μ l BP buffer and 1.5 μ l of BP clonase enzyme mix (Invitrogen) in a final volume of 10 μ l at RT for 1h. The reaction was stopped by addition of proteinase K (2 μ g) and incubated at 37°C for a further 10 min. An aliquot of this reaction (2 μ l) was used to transform *E. coli* DH10B cells by electroporation as follows: a 30 μ l aliquot of DH10B 15 electrocompetent cells (Invitrogen) was thawed on ice and 2 μ l of the BP reaction mix was added. The mixture was transferred to a chilled 0.1cm electroporation cuvette and the cells

recommended protocol. SOC media (0.5ml) which had been pre-warmed to room temperature was added immediately after electroporation. The mixture was transferred to a 20 15ml snap-cap tube and incubated, with shaking (220 rpm) for 1h at 37°C. Aliquots of the transformation mixture (10 μ l and 50 μ l) were then plated on L-broth (LB) plates containing kanamycin (40 μ g/ml) and incubated overnight at 37°C.

Plasmid mini-prep DNA was prepared from 5ml cultures from 6 of the resultant colonies using a Qiaprep Turbo 9600 robotic system (Qiagen). Plasmid DNA (200-500ng) was 25 subjected to DNA sequencing with 21M13 and M13Rev primers using the BigDyeTerminator system (Applied Biosystems cat. no. 4390246) according to the manufacturer's instructions. The primer sequences are shown in Table 1. Sequencing reactions were purified using Dye-Ex columns (Qiagen) or Montage SEQ 96 cleanup plates (Millipore cat. no. LSKS09624) then analyzed on an Applied Biosystems 3700 30 sequencer.

Plasmid eluate (2 μ l) from one of the clones which contained the correct sequence (pDONR221-INSP108-6HIS, plasmid ID 14224, figure 13) was then used in a

recombination reaction containing 1.5 μ l of either pEAK12d vector or pDEST12.2 vector (figures 11 & 12) (0.1 μ g / μ l), 2 μ l LR buffer and 1.5 μ l of LR clonase (Invitrogen) in a final volume of 10 μ l. The mixture was incubated at RT for 1h, stopped by addition of proteinase K (2 μ g) and incubated at 37°C for a further 10 min. An aliquot of this reaction (1 μ l) was 5 used to transform *E. coli* DH10B cells by electroporation as follows: a 30 μ l aliquot of DH10B electrocompetent cells (Invitrogen) was thawed on ice and 1 μ l of the LR reaction mix was added. The mixture was transferred to a chilled 0.1cm electroporation cuvette and the cells electroporated using a BioRad Gene-Pulser™ according to the manufacturer's recommended protocol. SOC media (0.5ml) which had been pre-warmed to room 10 temperature was added immediately after electroporation. The mixture was transferred to a 15ml snap-cap tube and incubated, with shaking (220 rpm) for 1h at 37°C. Aliquots of the transformation mixture (10 μ l and 50 μ l) were then plated on L-broth (LB) plates containing ampicillin (100 μ g/ml) and incubated overnight at 37°C.

Plasmid mini-prep DNA was prepared from 5ml cultures from 6 of the resultant colonies 15 subcloned in each vector using a Qiaprep Turbo 9600 robotic system (Qiagen). Plasmid DNA (200-500ng) in the pEAK12d vector was subjected to DNA sequencing with

pDEST12.2 vector was subjected to DNA sequencing with 21M13 and M13Rev primers as described above. Primers sequences are shown in Table 1.

20 CsCl gradient purified maxi-prep DNA was prepared from a 500ml culture of one of each of the sequence verified clones (pEAK12d-INSP108-6HIS, plasmid ID number 14228, figure 14, and pDEST12.2-INSP108-6HIS, plasmid ID 14229, figure 15) using the method described by Sambrook J. *et al.*, 1989 (in Molecular Cloning, a Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press). Plasmid DNA was resuspended at a 25 concentration of 1 μ g/ μ l in sterile water and stored at -20°C.

Table 1: INSP108 cloning and sequencing primers

| Primer | Sequence (5' - 3') |
|-------------|--|
| INSP108-CP1 | ATT GGT ATG GCC ACA AGG AG |
| INSP108-CP2 | CAC AAC TAT TTC CCA GTC AGT A |
| INSP108-EX1 | AA GCA GGC TTC <u>GCC ACC</u> ATG GCC ACA AGG AGC GTC CT |
| INSP108-EX2 | GTG ATG GTG ATG GTG TTC TGC CTC CTG CGT CTT GT |
| GCP Forward | G GGG ACA AGT TTG TAC AAA AAA GCA GGC TTC <u>GCC ACC</u> |
| GCP Reverse | GGG GAC CAC TTT GTA CAA GAA AGC TGG GTT TCA ATG GTG ATG GTG ATG GTG |
| PEAK12F | GCC AGC TTG GCA CTT GAT GT |
| PEAK12R | GAT GGA GGT GGA CGT GTC AG |
| 21M13 | TGT AAA ACG ACG GCC AGT |
| M13REV | CAG GAA ACA GCT ATG ACC |
| T7 | TAA TAC GAC TCA CTA TAG G |
| T3 | ATT AAC CCT CAC TAA AGG |

Underlined sequence = Kozak sequence

Bold = Stop codon

5 *Italic* sequence = His tag

Example 6: Cloning of INSP109 by exon assembly

1.1 PCR amplification of exons encoding INSP109 from genomic DNA.

PCR primers were designed to amplify exons 1 and 2 of INSP109 (table 2). The reverse primer for exon 1 (INSP109-exon1R) has an overlap of 9bp with exon 2 of INSP109 at its 5' end. The forward primer for exon 2 (INSP109-exon2F) has a 9bp overlap with exon 1 of INSP109 at its 5' end.

To generate exon 1 of INSP109, the PCR reaction was performed in a final volume of 50µl and contained 1µl of genomic DNA (0.1µg/µl (Novagen Inc.), 1.5µl of 10mM dNTPs (Amersham Pharmacia Biotech), 1µl of MgSO₄ (Invitrogen), 1.5µl of INSP109-exon1F (10µM), 1.5µl of INSP109-exon1R (10µM), 10µl of 10X Pfx buffer and 0.5µl of Pfx polymerase (2.5U/µl) (Invitrogen). The PCR conditions were 94°C for 5 min; 30 cycles of 94°C for 15s, 57°C for 30s and 68°C for 30 sec; an additional

elongation cycle of 68°C for 7 min; and a holding cycle of 4°C. Reaction products were loaded onto a 2% agarose gel (1X TAE) and PCR products of the correct size (64bp) were gel-purified using a Qiaquick Gel Extraction Kit (Qiagen cat. no. 28704) and eluted in 30μl of elution buffer (Qiagen). Exon 2 of INSP109 was produced and 5 purified using the same except that the PCR primers were INSP109-exon2F and INSP109-exon2R, and the annealing temperature used was 63°C. The INSP109 exon 2 PCR product was 190bp.

1.2 Assembly of exons 1 and 2 to generate the INSP109 ORF

Exons 1 and 2 were assembled in a 50μl PCR reaction containing 5μl of gel purified 10 exon 1, 5μl of gel purified exon 2, 1μl of 10mM dNTPs, 2μl of MgSO₄, 1μl of INSP109-exon1F (10μM), 1μl of INSP109-exon2R (10μM), 5μl of 10X Platinum Taq HiFi buffer, and 0.5μl of Platinum Taq HiFi DNA polymerase (5U/μl) (Invitrogen). The reaction conditions were: 94°C, 2 min; 35 cycles of 94°C for 30s, 60°C for 30s and 68°C for 1 min; an additional elongation cycle of 68°C for 7 min; and a holding cycle 15 of 4°C. Reaction products were analysed on a 2% agarose gel (1X TAE). PCR products of the correct size (236bp) were gel purified using the Qiagen MinElute DNA

10μl of EB buffer (10mM Tris.Cl, pH 8.5) and subcloned directly.

1.3 Subcloning of PCR Products

20 The PCR product was subcloned into the topoisomerase I modified cloning vector (pCR4-TOPO) purchased from the Invitrogen Corporation using the conditions specified by the manufacturer. Briefly, 4μl of gel purified PCR product was incubated for 15 min at room temperature with 1μl of TOPO vector and 1μl salt solution. The reaction mixture was then transformed into *E. coli* strain TOP10 (Invitrogen) as follows: a 50μl aliquot of One Shot 25 TOP10 cells was thawed on ice and 2μl of TOPO reaction was added. The mixture was incubated for 15 min on ice and then heat shocked by incubation at 42°C for exactly 30s. Samples were returned to ice and 250μl of warm (room temperature) SOC media was added. Samples were incubated with shaking (220 rpm) for 1h at 37°C. The transformation mixture was then plated on L-broth (LB) plates containing ampicillin (100μg/ml) and 30 incubated overnight at 37°C.

1.4 Colony PCR

Ampicillin resistant colonies were inoculated into 50 μ l sterile water using a sterile toothpick. A 10 μ l aliquot of the inoculum was then subjected to PCR in a total reaction volume of 20 μ l containing 1X AmpliTaqTM buffer, 200 μ M dNTPs, 20 pmoles T7 primer, 20 pmoles of T3 primer, 1 unit of AmpliTaqTM (Perkin Elmer) using an MJ Research 5 DNA Engine. The cycling conditions were as follows: 94°C, 2 min; 30 cycles of 94°C, 30 sec, 48°C, 30 sec and 72°C for 1 min. Samples were maintained at 4°C (holding cycle) before further analysis.

PCR reaction products were analyzed on 1% agarose gels in 1X TAE buffer. Colonies which gave the expected PCR product size (236bp cDNA + 103bp due to the multiple 10 cloning site or MCS) were grown up overnight at 37°C in 5 ml L-Broth (LB) containing ampicillin (100 μ g/ml), with shaking at 220 rpm.

1.5 Plasmid DNA preparation and sequencing

Miniprep plasmid DNA was prepared from 5ml cultures using a Qiaprep Turbo 9600 robotic system (Qiagen) or Wizard Plus SV Minipreps kit (Promega cat. no. 1460) 15 according to the manufacturer's instructions. Plasmid DNA was eluted in 100 μ l of sterile water. The DNA concentration was measured using an Eppendorf BO photometer. Plasmid DNA (200-500ng) was subjected to DNA sequencing using the BigDyeTerminator system (Applied Biosystems cat. no. 4390246) according to the manufacturer's instructions. The primer sequences are shown in Table 2. Sequencing 20 reactions were purified using Dye-Ex columns (Qiagen) or Montage SEQ 96 cleanup plates (Millipore cat. no. LSKS09624) then analyzed on an Applied Biosystems 3700 sequencer.

Sequence analysis identified a clone containing 100% match to the predicted INSP109 sequence. The sequence of the cloned cDNA fragment is shown in Figure 18. The plasmid 25 map of the cloned PCR product (pCR4-TOPO-INSP109) (plasmid ID.13984) is shown in Figure 19.

3. Construction of a plasmid for the expression of INSP109 in HEK293/EBNA cells.

A pCR4-TOPO clone containing the full coding sequence (ORF) of INSP109 identified by DNA sequencing (pCR4-TOPO-INSP109, plasmid ID.13984) (figure 19) was then used to 30 subclone the insert into the mammalian cell expression vectors pEAK12d (figure 11) and pDEST12.2 (figure 12) using the GatewayTM cloning methodology (Invitrogen).

2.1 Generation of Gateway compatible INSP109 ORF fused to an in frame 6HIS tag sequence.

The first stage of the Gateway cloning process involves a two step PCR reaction which generates the ORF of INSP109 flanked at the 5' end by an attB1 recombination site and 5 Kozak sequence, and flanked at the 3' end by a sequence encoding an in frame 6 histidine (6HIS) tag, a stop codon and the attB2 recombination site (Gateway compatible cDNA). The first PCR reaction (in a final volume of 50µl) contains: 1.5µl of pCR4-TOPO-INSP109 (plasmid ID 13984), 1.5µl dNTPs (10mM), 5µl of 10X Pfx polymerase buffer, 1µl MgSO₄ (50mM), 0.5µl each of gene specific primer (100µM) (INSP109-EX1 and 10 INSP109-EX2), 2.5µl 10X Enhancer™ solution (Invitrogen) and 1µl Platinum Pfx DNA polymerase (Invitrogen). The PCR reaction was performed using an initial denaturing step of 95°C for 2 min, followed by 15 cycles of 94°C for 15s; 55°C for 30s and 68°C for 2 min 30sec; and a holding cycle of 4°C. The amplification products were purified directly from the PCR mixture using the Wizard PCR Preps DNA Purification System (Promega) and 15 recovered in 50µl sterile water according to the manufacturer's instructions.

The second PCR reaction (in a final volume of 50µl) contained 10µl purified PCR 1 1 0.5µl of each Gateway conversion primer (100µM) (GCP forward and GCP reverse) and 0.5µl of Platinum Pfx DNA polymerase. The conditions for the 2nd PCR reaction were: 20 95°C for 1 min; 4 cycles of 94°C, 15 sec; 50°C, 30 sec and 68°C for 2 min 30sec; 19 cycles of 94°C, 15 sec; 55°C, 30 sec and 68°C, 2 min 30 sec; followed by a holding cycle of 4°C. PCR products were gel purified using the Wizard PCR prep DNA purification system (Promega) according to the manufacturer's instructions.

2.2 Subcloning of Gateway compatible INSP109 ORF into Gateway entry vector 25 pDONR221 and expression vectors pEAK12d and pDEST12.2

The second stage of the Gateway cloning process involves subcloning of the Gateway modified PCR product into the Gateway entry vector pDONR221 (Invitrogen, figure 10) as follows: 5µl of purified product from PCR2 were incubated with 1µl pDONR221 vector (0.15µg/µl), 2µl BP buffer and 1.5µl of BP clonase enzyme mix (Invitrogen) in a final 30 volume of 10µl at RT for 1h. The reaction was stopped by addition of proteinase K (2µg) and incubated at 37°C for a further 10 min. An aliquot of this reaction (2µl) was used to transform *E. coli* DH10B cells by electroporation as follows: a 30µl aliquot of DH10B

electrocompetent cells (Invitrogen) was thawed on ice and 2 μ l of the BP reaction mix was added. The mixture was transferred to a chilled 0.1cm electroporation cuvette and the cells electroporated using a BioRad Gene-Pulser™ according to the manufacturer's recommended protocol. SOC media (0.5ml) which had been pre-warmed to room temperature was added immediately after electroporation. The mixture was transferred to a 15ml snap-cap tube and incubated, with shaking (220 rpm) for 1h at 37°C. Aliquots of the transformation mixture (10 μ l and 50 μ l) were then plated on L-broth (LB) plates containing kanamycin (40 μ g/ml) and incubated overnight at 37°C.

Plasmid mini-prep DNA was prepared from 5ml cultures from 6 of the resultant colonies using a Qiaprep Turbo 9600 robotic system (Qiagen). Plasmid DNA (200-500ng) was subjected to DNA sequencing with 21M13 and M13Rev primers using the BigDyeTerminator system (Applied Biosystems cat. no. 4390246) according to the manufacturer's instructions. The primer sequences are shown in Table 2. Sequencing reactions were purified using Dye-Ex columns (Qiagen) or Montage SEQ 96 cleanup plates (Millipore cat. no. LSKS09624) then analyzed on an Applied Biosystems 3700 sequencer.

(pDONR221-INSPI09-6HIS, plasmid ID 14230, figure 20) was then used in a recombination reaction containing 1.5 μ l of either pEAK12d vector or pDEST12.2 vector (figures 11 & 12) (0.1 μ g/ μ l), 2 μ l LR buffer and 1.5 μ l of LR clonase (Invitrogen) in a final volume of 10 μ l. The mixture was incubated at RT for 1h, stopped by addition of proteinase K (2 μ g) and incubated at 37°C for a further 10 min. An aliquot of this reaction (1 μ l) was used to transform *E. coli* DH10B cells by electroporation as follows: a 30 μ l aliquot of DH10B electrocompetent cells (Invitrogen) was thawed on ice and 1 μ l of the LR reaction mix was added. The mixture was transferred to a chilled 0.1cm electroporation cuvette and the cells electroporated using a BioRad Gene-Pulser™ according to the manufacturer's recommended protocol. SOC media (0.5ml) which had been pre-warmed to room temperature was added immediately after electroporation. The mixture was transferred to a 15 ml snap-cap tube and incubated, with shaking (220 rpm) for 1h at 37°C. Aliquots of the transformation mixture (10 μ l and 50 μ l) were then plated on L-broth (LB) plates containing ampicillin (100 μ g/ml) and incubated overnight at 37°C.

Plasmid mini-prep DNA was prepared from 5ml cultures from 6 of the resultant colonies subcloned in each vector using a Qiaprep Turbo 9600 robotic system (Qiagen). Plasmid DNA (200-500ng) in the pEAK12d vector was subjected to DNA sequencing with pEAK12F and pEAK12R primers as described above. Plasmid DNA (200-500ng) in the 5 pDEST12.2 vector was subjected to DNA sequencing with 21M13 and M13Rev primers as described above. Primers sequences are shown in Table 2.

CsCl gradient purified maxi-prep DNA was prepared from a 500ml culture of one of each of the sequence verified clones (pEAK12d-INSPI09-6HIS, plasmid ID number 14231, figure 21, and pDEST12.2-INSPI09-6HIS, plasmid ID 14350, figure 22) using the method 10 described by Sambrook J. *et al.*, 1989 (in Molecular Cloning, a Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press). Plasmid DNA was resuspended at a concentration of 1µg/µl in sterile water and stored at -20°C.

Table 2: Primers for INSP109 cloning and sequencing

| Primer | Sequence (5'-3') |
|-----------------|--|
| GCP Forward | G GGG ACA AGT TTG TAC AAA AAA GCA GGC TTC <u>GCC ACC</u> |
| GCP Reverse | GGG GAC CAC TTT GTA CAA GAA AGC TGG GTT TCA ATG GTG ATG GTG ATG GTG |
| INSP109-exon1F | ATG AAC CTC TGT CTT TCT GCA TTA CTC |
| INSP109-exon1R | TAC GTT TTC CTG AAG GCA GTA AGA TCA C |
| INSP109- exon2F | GCG TTT AGA GAA AAG GTA TGT TTG GGA ATG |
| INSP109- exon2R | TAA TGA ACC CAT GGA TCT TTG GCT TGC GG |
| INSP109-EX1 | GCA GGC TTC <u>GCC ACC</u> ATG AAC CTC TGT CTT TCT GC |
| INSP109-EX2 | <u>GTG</u> ATG GTG ATG GTG ATG AAC CCA TGG ATC TTT GG |

| | |
|----------|-----------------------------------|
| PEAK12-R | GAT GGA GGT GGA CGT GTC AG |
| PENTR-F | TCG CGT TAA CGC TAG CAT GGA TCT C |
| PENTR-R | GTA ACA TCA GAG ATT TTG AGA CAC |
| T7 | TAA TAC GAC TCA CTA TAG GG |
| T3 | CTC CCT TTA GTG AGG GTA ATT |

- 5 Underlined sequence = Kozak sequence
Bold = Stop codon
Italic sequence = His tag
Highlighted sequence = overlap with adjacent exon

Example 7: Expression and purification of INSP108 and INSP109

Further experiments may now be performed to determine the tissue distribution and expression levels of the INSP108 and INSP109 polypeptides *in vivo*, on the basis of the nucleotide and amino acid sequence disclosed herein.

- 5 The presence of the transcripts for INSP108 and INSP109 may be investigated by PCR of cDNA from different human tissues. The INSP108 and INSP109 transcripts may be present at very low levels in the samples tested. Therefore, extreme care is needed in the design of experiments to establish the presence of a transcript in various human tissues as a small amount of genomic contamination in the RNA preparation will provide a false positive result. Thus, all RNA should be treated with DNase prior to use for reverse transcription. In addition, for each tissue a control reaction may be set up in which reverse transcription was not undertaken (a -ve RT control).
- 10

For example, 1 µg of total RNA from each tissue may be used to generate cDNA using Multiscript reverse transcriptase (ABI) and random hexamer primers. For each tissue, a control reaction is set up in which all the constituents are added except the reverse transcriptase (-ve RT control). PCR reactions are set up for each tissue on the reverse transcribed RNA samples and the results are evaluated. A primer sequence may readily be designed on the basis of the sequence information provided herein. The presence of a product of the correct molecular weight in the reverse transcribed sample together with the absence of a product in the minus RT control may be taken as evidence for the presence of a transcript in that tissue. Any suitable cDNA libraries may be used to screen for the INSP108 and INSP109 transcripts, not only those generated as described above.

The tissue distribution pattern of the INSP108 and INSP109 polypeptides will provide further useful information in relation to the function of those polypeptides.

- 25 In addition, further experiments may now be performed using the pEAK12d-INSP108-6HIS, pEAK12d-INSP109-6HIS, pDEST12.2-INSP108-6HIS and pDEST12.2-INSP109-6HIS expression vectors. Transfection of mammalian cell lines with these vectors may enable the high level expression of the INSP108 and INSP109 proteins and thus enable the continued investigation of the functional characteristics of the INSP108 and INSP109 polypeptides. The following material and methods are an example of those suitable in such experiments:
- 30

Cell Culture.

Human Embryonic Kidney 293 cells expressing the Epstein-Barr virus Nuclear Antigen (HEK293-EBNA, Invitrogen) are maintained in suspension in Ex-cell VPRO serum-free medium (seed stock, maintenance medium, JRH). Sixteen to 20 hours prior to transfection (Day-1), cells are seeded in 2x T225 flasks (50ml per flask in DMEM / F12 (1:1) containing 2% FBS seeding medium (JRH) at a density of 2×10^5 cells/ml). The next day (transfection day 0) transfection takes place using the JetPEITM reagent (2 μ l/ μ g of plasmid DNA, PolyPlus-transfection). For each flask, plasmid DNA is co-transfected with GFP (fluorescent reporter gene) DNA. The transfection mix is then added to the 2xT225 flasks and incubated at 37°C (5%CO₂) for 6 days. Confirmation of positive transfection may be carried out by qualitative fluorescence examination at day 1 and day 6 (Axiovert 10 Zeiss).

On day 6 (harvest day), supernatants from the two flasks are pooled and centrifuged (e.g. 4°C, 400g) and placed into a pot bearing a unique identifier. One aliquot (500 μ l) is kept for QC of the 6His-tagged protein (internal bioprocessing QC).

15 Scale-up batches may be produced by following the protocol called "PEI transfection of suspension cells", referenced BP/PEI/HH/02/04, with PolyEthyleneImine from ~~Invitrogen~~.

Purification process

The culture medium sample containing the recombinant protein with a C-terminal 6His tag is diluted with cold buffer A (50mM NaH₂PO₄; 600mM NaCl; 8.7 % (w/v) glycerol, pH 7.5). The sample is filtered then through a sterile filter (Millipore) and kept at 4°C in a sterile square media bottle (Nalgene).

20 The purification is performed at 4°C on the VISION workstation (Applied Biosystems) connected to an automatic sample loader (Labomatic). The purification procedure is composed of two sequential steps, metal affinity chromatography on a Poros 20 MC (Applied Biosystems) column charged with Ni ions (4.6 x 50 mm, 0.83ml), followed by gel filtration on a Sephadex G-25 medium (Amersham Pharmacia) column (1,0 x 10cm).

25 For the first chromatography step the metal affinity column is regenerated with 30 column volumes of EDTA solution (100mM EDTA; 1M NaCl; pH 8.0), recharged with Ni ions through washing with 15 column volumes of a 100mM NiSO₄ solution, washed with 10 column volumes of buffer A, followed by 7 column volumes of buffer B (50 mM

- NaH₂PO₄; 600mM NaCl; 8.7 % (w/v) glycerol, 400mM; imidazole, pH 7.5), and finally equilibrated with 15 column volumes of buffer A containing 15mM imidazole. The sample is transferred, by the Labomatic sample loader, into a 200ml sample loop and subsequently charged onto the Ni metal affinity column at a flow rate of 10ml/min. The column is
- 5 washed with 12 column volumes of buffer A, followed by 28 column volumes of buffer A containing 20mM imidazole. During the 20mM imidazole wash loosely attached contaminating proteins are eluted from the column. The recombinant His-tagged protein is finally eluted with 10 column volumes of buffer B at a flow rate of 2ml/min, and the eluted protein is collected.
- 10 For the second chromatography step, the Sephadex G-25 gel-filtration column is regenerated with 2ml of buffer D (1.137M NaCl; 2.7mM KCl; 1.5mM KH₂PO₄; 8mM Na₂HPO₄; pH 7.2), and subsequently equilibrated with 4 column volumes of buffer C (137mM NaCl; 2.7mM KCl; 1.5mM KH₂PO₄; 8mM Na₂HPO₄; 20% (w/v) glycerol; pH 7.4). The peak fraction eluted from the Ni-column is automatically loaded onto the
- 15 Sephadex G-25 column through the integrated sample loader on the VISION and the protein is eluted with buffer C at a flow rate of 2 ml/min. The fraction was filtered through
- sample is analyzed on SDS-PAGE (4-12% NuPAGE gel; Novex) Western blot with anti-His antibodies. The NuPAGE gel may be stained in a 0.1 % Coomassie blue R250 staining
- 20 solution (30% methanol, 10% acetic acid) at room temperature for 1h and subsequently destained in 20% methanol, 7.5% acetic acid until the background is clear and the protein bands clearly visible.
- Following the electrophoresis the proteins are electrotransferred from the gel to a nitrocellulose membrane. The membrane is blocked with 5% milk powder in buffer E
- 25 (137mM NaCl; 2.7mM KCl; 1.5mM KH₂PO₄; 8mM Na₂HPO₄; 0.1 % Tween 20, pH 7.4) for 1h at room temperature, and subsequently incubated with a mixture of 2 rabbit polyclonal anti-His antibodies (G-18 and H-15, 0.2µg/ml each; Santa Cruz) in 2.5% milk powder in buffer E overnight at 4°C. After a further 1 hour incubation at room temperature, the membrane is washed with buffer E (3 x 10min), and then incubated with a
- 30 secondary HRP-conjugated anti-rabbit antibody (DAKO, HRP 0399) diluted 1/3000 in buffer E containing 2.5% milk powder for 2 hours at room temperature. After washing with buffer E (3 x 10 minutes), the membrane is developed with the ECL kit (Amersham

Pharmacia) for 1 min. The membrane is subsequently exposed to a Hyperfilm (Amersham Pharmacia), the film developed and the western blot image visually analysed.

For samples that showed detectable protein bands by Coomassie staining, the protein concentration may be determined using the BCA protein assay kit (Pierce) with bovine serum albumin as standard.

Furthermore, overexpression or knock-down of the expression of the polypeptides in cell lines may be used to determine the effect on transcriptional activation of the host cell genome. Dimerisation partners, co-activators and co-repressors of the INSP108 and INSP109 polypeptide may be identified by immunoprecipitation combined with Western blotting and immunoprecipitation combined with mass spectroscopy.

Example 8: Assays for the detection of defensin activity

Cell- and Animal-based assay for the validation and characterization of the chemokine-like polypeptides.

Several assays have been developed for testing specificity, potency, and efficacy of chemokines using cell cultures or animal models, for example *in vitro* chemotaxis assays

Biol Chem, 270: 2716-21, 1995), or mouse ear swelling (Garrigue JL et al., Contact Dermatitis, 30: 231-7, 1994). Many other assays and technologies for generating useful tools and products (antibodies, transgenic animals, radiolabeled proteins, etc.) have been described in reviews and books dedicated to chemokines (Methods Mol. Biol vol. 138, "Chemokines Protocols", edited by Proudfoot AJ et al., Humana Press Inc., 2000; Methods Enzymol, vol. 287 and 288, Academic Press, 1997), and can be used to verify, in a more precise manner, the biological activities of the chemokine-like polypeptides of the invention and related reagents in connection with possible therapeutic or diagnostic methods and uses.

Cytokine Expression modulation assays

The following *in vitro* cell-based tri-replicas assays measure the effects of the protein of the invention on cytokine secretion induced by Concanavalin A (Con A) acting on different human peripheral blood mononuclear cells (hPBMC) cells as measured by a cytokine bead array (CBA) assay for IL-2, IFN- γ , TNF- α , IL-5, IL-4 and IL-10 such as the Human Th1/Th2 Cytokine CBA kit (Becton-Dickinson).

The optimal conditions are 100 000 cells/well in 96-well plates and 100 μ l final in 2 % glycerol. The optimal concentration of mitogen (ConA) is 5 ng/ml. The optimal time for the assay is 48 h. The read-out choice is the CBA.

1 Purification of Human PBMC from a buffy coat

5 The buffy coat 1 to 2 is diluted with DMEM. 25ml of diluted blood was thereafter slowly added onto a 15ml layer of Ficoll in a 50 ml Falcon tube, and tubes are centrifuged (2000 rpm, 20 min, at RT without brake). The interphase (ring) is then collected and the cells are washed with 25 ml of DMEM followed by a centrifuge step (1200 rpm, 5 min). This procedure is repeated three times. A buffy coat gives approximately 600×10^6 total cells.

10 2 Screening

80 μ l of 1.25×10^6 cells/ml are diluted in DMEM+2.5% Human Serum+1% L-Glutamine+1% Penicillin-Streptomycin and thereafter added to a 96 well microtiter plate.

10 μ l are added per well (one condition per well): Proteins were diluted in PBS+20%Glycerol (the final dilution of the proteins is 1/10).

15 10 μ l of the ConA Stimulant (50 μ g/ml) are then added per well (one condition per well -

After 48 h, cell supernatants are collected and human cytokines are measured by Human Th1/Th2 Cytokine CBA Kit Becton-Dickinson.

3 CBA analysis

20 (for more details, refer to the manufacturer's instructions in the CBA kit)

i) Preparation of mixed Human Th1/Th2 Capture Beads

The number of assay tubes that are required for the experiment are determined.

Each capture bead suspension is vigorously vortexed for a few seconds before mixing. For each assay to be analysed, 10 μ l aliquot of each capture bead are added into a single tube

25 labelled "mixed capture beads". The Bead mixture is thoroughly vortexed.

ii) Preparation of test samples

Supernatants are diluted (1:4) using the Assay Diluent (20 μ l of supernatants + 60 μ l of Assay Diluent). The sample dilution is then mixed before transferring samples into a 96 well conical bottomed microtiter plate (Nunc).

iii) Human Th1/Th2 Cytokine CBA Assay Procedure

50µl of the diluted supernatants are added into a 96 well conical bottomed microtiter plate (Nunc). 50µl of the mixed capture beads are added followed by 50µl addition of the Human Th1/Th2 PE Detection Reagent. The plate is then incubated for 3 hours at RT and
5 protected from direct exposure to light followed by centrifugation at 1500rpm for 5 minutes. The supernatant is then carefully discarded. In a subsequent step, 200µl of wash buffer are twice added to each well, centrifuged at 1500rpm for 5 minutes and supernatant carefully discarded. 130µl of wash buffer are thereafter added to each well to resuspend the bead pellet. The samples are finally analysed on a flow cytometer. The data are then
10 analysed using the CBA Application Software, Activity Base and Microsoft Excel software.

From the read-out of the assay it can be evaluated whether *in vitro*, the protein of the invention has a consistent inhibitory effect on all cytokines tested (IFN- γ , TNF- α , IL-2, IL-4, IL-5, IL-10).

15 Moreover, based on the EC50 value, it can be easily evaluated which cytokine is inhibited the most and then derive the specific auto-immune / inflammatory disease which is known to be particularly linked to that cytokine.

Assays targeting T lymphocyte responses

20 **Fas-Ligand-induced T cell death.** This assay will reveal new modulators of receptor mediated cell death.

In this assay, T cell apoptosis is induced by stimulating Jurkat cells (a human T cell line) with recombinant 6 Histidine-tagged Fas Ligand combined with a monoclonal anti 6-his antibody. Death is quantified by release of LDH, a cytoplasmic enzyme released in the
25 culture medium when cells are dying. The read out is a colorimetric assay read at 490nm.T cells have been shown to be pathogenic in many autoimmune diseases, being able to control antigen-specific T cell death is a therapeutic strategy (e.g. anti-TNF α treatment in patient with Crohn's disease).

30 **Human-MLR: proliferation and cytokine secretion.** This cell-based assay measures the effects of novel proteins on lymphocyte proliferation and cytokine secretion or inhibition

upon stimulation by PBMC from another donor (alloreactivity). These assay address antigen-specific T cell and antigen presenting cell functions, which are crucial cellular responses in any autoimmune diseases. Secreted cytokine (IL-2, 4, 5, 10, TNF- α and IFN- γ) are quantified by CBA.

- 5 Note: proliferation and cytokine secretion are independent responses.

Mouse-MLR: proliferation. This cell-based assay measures the effects of novel proteins on lymphocyte proliferation or inhibition of mouse spleen cells following stimulation by spleen cells from another donor (mouse strain). This cell-based assay measures the effect of novel proteins on T lymphocyte and antigen presenting cell responses and will be used
10 to confirm activity of positives and hits identify in the h-MLR assays. This assay will be used to select proteins that will be tested in murine model of human diseases.

Human PBMC stimulated with the superantigen, TSST.

Superantigens are strong modulators of the immune system affecting T cells. Superantigens influence immunologically mediated disorders such as IBD, inflammatory
15 skin diseases like atopic dermatitis and psoriasis. In this cellular assay, we are specifically

cell response to classical antigens, in particular in respect to co-stimulatory molecules.

Human PBMC stimulated with either ConA or PHA. These cell-based assays measure the effects of novel proteins on cytokine secretion induced by two different stimuli acting
20 on different cells as measured by a cytokine bead array (CBA) assay (IL-2, IFN- γ , TNF- α , IL-5, IL-4 and IL-10).

Most of cytokines can have dual actions, pro or anti-inflammatory, depending of the injury, milieu and cellular target. Any protein with the capability to modulate cytokine secretion may have a therapeutic potential (e.g. decreasing IFN- γ and TNF- α would be
25 beneficial in Th1-mediated autoimmune disease in contrast decreasing IL-4, IL-5 may be beneficial in Th2-mediated-diseases, inducing IL-10 would interesting in MS and SLE).

Assays targeting monocyte/macrophages and granulocyte responses

Human PBMC stimulated with LPS. This cell-based assay measures the effects of novel
30 proteins on cytokine secretion (IFN- γ , TNF- α) induced by LPS acting on monocytes/macrophages and granulocytes.

Any protein with the capability to modulate IFN- γ and TNF- α secretion would be beneficial in Th1-mediated autoimmune diseases.

Assays targeting neutrophil responses

Neutrophils are important in inflammation and autoimmune diseases such as Rheumatoid

- 5 Arthritis. Leukocyte chemo-attractants such as IL-8 initiate a sequence of adhesive interactions between cells and the micro-vascular endothelium, resulting in activation, adhesion and finally migration of neutrophils. The tissue infiltration of neutrophils depends on a reorganisation of cytoskeleton elements associated with specific changes in cell morphology of these cells.
- 10 This cell-based assay measures the effect of novel proteins on cytoskeleton reorganization of human neutrophils.

Assays targeting B lymphocyte responses

Autoantibodies as well as infiltrating B cells are thought to be important in the pathogenesis of various autoimmune diseases, such as systemic lupus erythematosus (SLE),

- 15 rheumatoid arthritis (RA), Sjogren's syndrome and myasthenia gravis. Compelling

leading to the inappropriate survival of autoreactive B cells producing pathogenic antibodies and sustained inflammation. The identification of new factors that play critical roles in the regulation of B cell proliferation, survival and differentiation following B cell

- 20 receptor triggering are of high relevance in the development of novel therapies.

B cell proliferation. This cell-based assay measures the effect of novel proteins on B cell survival.

B cell co-stimulation. This cell-based assay measures the effect of novel proteins on B cell co-stimulation.

25

Assays targeting monocytes and microglial responses

THP-1 calcium flux. The Ca⁺-flux in THP1-cell assay measures the effects of novel proteins on their ability to trigger an intracellular calcium release (a generic second messenger events) from the endoplasmic reticulum.

- 30 **Microglia cell proliferation (will be presented to the next IAC).**

During proliferation of microglial progenitors, a number of colony-stimulating factors, including some cytokines, are known to play key roles. Among them, M-CSF is crucial for the final step of maturation of macrophages/microglia and is not replaceable by any other factor. The evaluation of this biological response may represent a way to influence the 5 microglial activity and therefore an opportunity to identify molecules with therapeutic potential fro MS.

A cell-based assay was developed to measure the proliferative response of a microglia cell line to M-CSF. The feasibility and the robustness phases showed optimal results. This assay is in 96 well plates; non-radioactive substrate is required, easily automated.

List of INSP108 and INSP109 sequences (Sequence Listing):**SEQ ID NO: 1 (INSP108 nucleotide sequence exon 1)**

1 ATGGCCACAA GGAGCGTCCT CTTGCCCTC GTGGTCCTTA ACTTACTCTT
51 CTATGTTCCA CCAG

5

SEQ ID NO: 2 (INSP108 polypeptide sequence exon 1)

1 MATRSVLLAL VVLNLLFYVP PG

SEQ ID NO: 3 (INSP108 nucleotide sequence exon 2)

10 1 GTAGAAGTGG ACCCAATGTC TACATACAAA AAATCTTGC TTCATGTTGG
51 CGACTGCAAG GTACTTGCCG GCCAAAATGT CTAAAAAACG AACAAATATCG
101 TATTTGTGT GATACTATAC ATTTGTGCTG TGTAAACCCA AAATATTTAC
151 CTATACTGAC TGGGAAATAG

15 SEQ ID NO: 4 (INSP108 polypeptide sequence exon 2)

1 RSGPNVYIQLK IFASCWRLQG TCRPKCLKNE QYRILCDTIH LCCVNPKYLP
51 ILTGK*

SEQ ID NO: 5 (INSP108 nucleotide sequence)

20 1 ATGGCCACAA GGAGCGTCCT CTTGCCCTC GTGGTCCTTA ACTTACTCTT
101 TTGCTTCATG TTGGGGAGTG CAAAGTACTT CCCCCCCCCC AGGGGGGGGG
151 AACGAACAAT ATCGTATTGT GTGTGATACT ATACATTTGT GCTGTGTAAA
201 CCCAAAATAT TTACCTATAC TGACTGGGAA ATAG

25

SEQ ID NO: 6 (INSP108 polypeptide sequence)

1 MATRSVLLAL VVLNLLFYVP PGRSGPNVYI QKIFASCWRL QGTCRPKCLK
51 NEQYRILCDT IHLCVNPKY LPILTGK*

30 SEQ ID NO: 7 (INSP108 mature nucleotide sequence)

1 GGACCCAATG TCTACATACA AAAAATCTTT GCTTCATGTT GGCAGTGCA
51 AGGTACTTGC CGGCCAAAAT GTCTAAAAAA CGAACAAATAT CGTATTTGT
101 GTGATACTAT ACATTTGTGC TGTGTAAACC CAAAATATTT ACCTATACTG
151 ACTGGGAAAT AG

35

SEQ ID NO: 8 (INSP108 mature polypeptide sequence)

1 GPNVYIQLKIF ASCWRLQGTC RPKCLKNEQY RILCDTIHLC CVNPKYLPIL
51 TGK*

40

SEQ ID NO: 9 (INSP109 nucleotide sequence exon 1)

1 ATGAACCTCT GTCTTTCTGC ATTACTCTTC TTCCCTGGTGA TCTTACTGCC
51 TTCAG

5 SEQ ID NO: 10 (INSP109 polypeptide sequence exon 1)

1 MNLLSALLF FLVILLPSG

SEQ ID NO: 11 (INSP109 nucleotide sequence exon 2)

1 GAAAAGGTAT GTTTGGGAAT GATGGAGTCA AAGTTCGCAC CTGCACTAGC
10 51 CAGAAAGCCG TATGTTTCTT CGGGTGTCCG CCAGGATACA GGTGGATTGC
101 GTTCTGCCAC AATATTCTGT CTTGCTGTAA AAATATGACA CGTTTTCAAC
151 CCCCGCAAGC CAAAGATCCA TGGGTTCAATT AA

SEQ ID NO: 12 (INSP109 polypeptide sequence exon 2)

15 1 KGMFGNDGVK VRTCTSOKAV CFFGCPPGYR WIAFCHNILS CCKNMTRFQP
51 PQAKDPWVH*

SEQ ID NO: 13 (INSP109 nucleotide sequence)

1 ATGAACCTCT GTCTTTCTGC ATTACTCTTC TTCCCTGGTGA TCTTACTGCC
20 51 TTCAGGAAAA GGTATGTTTG GGAATGATGG AGTCAAAGTT CGCACCTGCA
101 CTACCCCTGAA ACCCGTATGT TTCTTCTGGGT GTCCGCCAGG ATACAGGTGG
201 TCAACCCCCG CAAGCCAAAG ATCCATGGGT TCATTAA

25 SEQ ID NO: 14 (INSP109 polypeptide sequence)

1 MNLLSALLF FLVILLPSGK GMFGNDGVKV RTCTSOKAVC FFGCPPGYRW
51 IAFCHNILSC CKNMTRFQPP QAKDPWVH*

SEQ ID NO: 15 (INSP109 mature nucleotide sequence)

30 1 ATGTTGGGA ATGATGGAGT CAAAGTTCGC ACCTGCACTA GCCAGAAAGC
51 CGTATGTTTC TTCCGGGTGTC CGCCAGGATA CAGGTGGATT GCGTTCTGCC
101 ACAATATTCT GTCTTGCTGT AAAAATATGA CACGTTTCA ACCCCCGCAA
151 GCCAAAGATC CATGGGTTCA TTAA

35 SEQ ID NO: 16 (INSP109 mature polypeptide sequence)

1 MFGNDGVKVR TCTSOKAVCF FGCPPGYRWI AFCHNILSCC KNMTRFQPPQ
51 AKDPWVH*

CLAIMS

1. A polypeptide, which polypeptide:

- (i) comprises the amino acid sequence as recited in SEQ ID NO:6 and/or SEQ ID NO:8;
- 5 (ii) is a fragment thereof which functions as a member of the defensin family of proteins, or having an antigenic determinant in common with the polypeptide of (i); or
- (iii) is a functional equivalent of (i) or (ii).

2. A polypeptide according to claim 1 which consists of the amino acid sequence as recited
10 in SEQ ID NO:6 and/or SEQ ID NO:8.

3. A polypeptide, which polypeptide:

- (i) comprises the amino acid sequence as recited in SEQ ID NO:14 and/or SEQ ID NO:16;
- (ii) is a fragment thereof which functions as a member of the defensin family of (i); or
- (iii) is a functional equivalent of (i) or (ii).

4. A polypeptide according to claim 3 which consists of the amino acid sequence as recited
in SEQ ID NO:14 and/or SEQ ID NO:16.

20 5. A polypeptide which is a functional equivalent according to part (iii) of claim 1 or claim 3, characterised in that it is homologous to the amino acid sequence as recited in SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:14 or SEQ ID NO:16 and is a member of the defensin family of proteins.

25 6. A polypeptide which is a fragment or a functional equivalent as recited in any one of claims 1, 3 or 5, which has greater than 80% sequence identity with the amino acid sequence recited in SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:14 or SEQ ID NO:16 or with an active fragment thereof, preferably greater than 85%, 90%, 95%, 98% or 99% sequence identity.

7. A polypeptide which is a functional equivalent as recited in any one of claims 1, 3, 5 or 6, which exhibits significant structural homology with a polypeptide having the amino acid sequence recited SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:14 or SEQ ID NO:16.
 8. A polypeptide which is a fragment as recited in any one of claims 1, 3 and claim 6
5 having an antigenic determinant in common with the polypeptide of part (i) of claim 1 or claim 3 which consists of 7 or more amino acid residues from the amino acid sequence recited in SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:14 or SEQ ID NO:16 .
 9. A purified nucleic acid molecule which encodes a polypeptide according to any one of the preceding claims.
 - 10 10. A purified nucleic acid molecule according to claim 9, which comprises the nucleic acid sequence as recited in SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:13 and/or SEQ ID NO:15, or is a redundant equivalent or fragment thereof.
 11. A purified nucleic acid molecule according to claim 9 or claim 10 which consists of the nucleic acid sequence as recited in SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:13 and/or
15 SEQ ID NO:15, or is a redundant equivalent or fragment thereof.
- with a nucleic acid molecule according to any one of claims 9 to 11.
13. A vector comprising a nucleic acid molecule as recited in any one of claims 9 to 12.
 14. A host cell transformed with a vector according to claim 13.
 - 20 15. A ligand which binds specifically to the defensin polypeptide according to any one of claims 1 to 8.
 16. A ligand according to claim 15, which is an antibody.
 17. A compound that either increases or decreases the level of expression or activity of a polypeptide according to any one of claims 1 to 8.
 - 25 18. A compound according to claim 17 that binds to a polypeptide according to any one of claims 1 to 8 without inducing any of the biological effects of the polypeptide.
 19. A compound according to claim 18, which is a natural or modified substrate, ligand, enzyme, receptor or structural or functional mimetic.
 20. A polypeptide according to any one of claims 1 to 8, a nucleic acid molecule according

to any one of claims 9 to 12, a vector according to claim 13, a host cell according to claim 14, a ligand according to claim 15 or claim 16, or a compound according to any one of claims 17 to 19, for use in therapy or diagnosis of disease.

21. A method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to any one of claims 1 to 8, or assessing the activity of a polypeptide according to any one of claims 1 to 8, in tissue from said patient and comparing said level of expression or activity to a control level, wherein a level that is different to said control level is indicative of disease.
5
22. A method according to claim 21 that is carried out *in vitro*.
- 10 23. A method according to claim 21 or claim 22, which comprises the steps of: (a) contacting a ligand according to claim 15 or claim 16 with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.
24. A method according to claim 21 or claim 22, comprising the steps of:
15 a) contacting a sample of tissue from the patient with a nucleic acid probe under acid molecule according to any one of claims 9 to 12 and the probe;
 b) contacting a control sample with said probe under the same conditions used in step a); and
- 20 c) detecting the presence of hybrid complexes in said samples; wherein detection of levels of the hybrid complex in the patient sample that differ from levels of the hybrid complex in the control sample is indicative of disease.
25. A method according to claim 21 or claim 22, comprising:
 a) contacting a sample of nucleic acid from tissue of the patient with a nucleic acid primer under stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule according to any one of claims 9 to 12 and the primer;
 b) contacting a control sample with said primer under the same conditions used in step a); and
 c) amplifying the sampled nucleic acid; and
30 d) detecting the level of amplified nucleic acid from both patient and control samples;

wherein detection of levels of the amplified nucleic acid in the patient sample that differ significantly from levels of the amplified nucleic acid in the control sample is indicative of disease.

26. A method according to claim 21 or claim 22 comprising:

- 5 a)obtaining a tissue sample from a patient being tested for disease;
 - b)isolating a nucleic acid molecule according to any one of claims 9 to 12 from said tissue sample; and
 - c)diagnosing the patient for disease by detecting the presence of a mutation which is associated with disease in the nucleic acid molecule as an indication of the disease.
- 10 27. The method of claim 26, further comprising amplifying the nucleic acid molecule to form an amplified product and detecting the presence or absence of a mutation in the amplified product.
28. The method of claim 26 or claim 27, wherein the presence or absence of the mutation in the patient is detected by contacting said nucleic acid molecule with a nucleic acid probe that hybridises to said nucleic acid molecule under stringent conditions to form a
- 15 ~~hybridised portion of the nucleic acid probe strand at any portion corresponding to a mutation associated with disease; and detecting the presence or absence of an unhybridised portion of the probe strand as an indication of the presence or absence of a disease-associated mutation.~~
- 20 ~~unhybridised portion of the nucleic acid probe strand at any portion corresponding to a mutation associated with disease; and detecting the presence or absence of an unhybridised portion of the probe strand as an indication of the presence or absence of a disease-associated mutation.~~
29. A method according to any one of claims 21 to 28, wherein said disease includes, but is not limited to, cell proliferative disorders, including neoplasm, melanoma, lung, colorectal, breast, pancreas, head and neck and other solid tumours; myeloproliferative disorders, such as leukemia, non-Hodgkin lymphoma, leukopenia, thrombocytopenia,
- 25 angiogenesis disorder, Kaposi's sarcoma; autoimmune/inflammatory disorders, including allergy, inflammatory bowel disease, arthritis, psoriasis and respiratory tract inflammation, asthma, and organ transplant rejection; cardiovascular disorders, including hypertension, oedema, angina, atherosclerosis, thrombosis, sepsis, shock, reperfusion injury, and ischemia; neurological disorders including central nervous system disease, Alzheimer's disease, brain injury, amyotrophic lateral sclerosis, and pain; developmental disorders; metabolic disorders including diabetes mellitus,
- 30

- osteoporosis, and obesity, AIDS and renal disease; infections including viral infection, bacterial infection, fungal infection, parasitic infection, sublethal endotoxaemia, septic shock, microbial infection of the amniotic cavity, Jarish-Herxheimer reaction of relapsing fever, infectious diseases of the central nervous system, acute pancreatitis, 5 ulcerative colitis, empyema, haemolytic uraemic syndrome, meningococcal disease, gastric infection, pertussis, peritonitis, psoriasis, rheumatoid arthritis, sepsis, asthma, HIV and glomerulonephritis.
30. A method according to any one of claims 21 to 28, wherein said disease is a disease in which defensins are implicated.
- 10 31. Use of a polypeptide according to any one of claims 1 to 8 as a defensin protein.
32. A pharmaceutical composition comprising a polypeptide according to any one of claims 1 to 8, a nucleic acid molecule according to any one of claims 9 to 12, a vector according to claim 13, a host cell according to claim 14, a ligand according to claim 15 or claim 16, or a compound according to any one of claims 17 to 19.
- 15 33. A vaccine composition comprising a polypeptide according to any one of claims 1 to 8
34. A polypeptide according to any one of claims 1 to 8, a nucleic acid molecule according to any one of claims 9 to 12, a vector according to claim 13, a host cell according to claim 14, a ligand according to claim 15 or claim 16, a compound according to any one 20 of claims 17 to 19, or a pharmaceutical composition according to claim 32, for use in the manufacture of a medicament for the treatment of cell proliferative disorders, including neoplasm, melanoma, lung, colorectal, breast, pancreas, head and neck and other solid tumours; myeloproliferative disorders, such as leukemia, non-Hodgkin lymphoma, leukopenia, thrombocytopenia, angiogenesis disorder, Kaposi's sarcoma; 25 autoimmune/inflammatory disorders, including allergy, inflammatory bowel disease, arthritis, psoriasis and respiratory tract inflammation, asthma, and organ transplant rejection; cardiovascular disorders, including hypertension, oedema, angina, atherosclerosis, thrombosis, sepsis, shock, reperfusion injury, and ischemia; neurological disorders including central nervous system disease, Alzheimer's disease, brain injury, amyotrophic lateral sclerosis, and pain; developmental disorders; 30 metabolic disorders including diabetes mellitus, osteoporosis, and obesity, AIDS and renal disease; infections including viral infection, bacterial infection, fungal infection,

- parasitic infection, sublethal endotoxaemia, septic shock, microbial infection of the amniotic cavity, Jarish-Herxheimer reaction of relapsing fever, infectious diseases of the central nervous system, acute pancreatitis, ulcerative colitis, empyaema, haemolytic uraemic syndrome, meningococcal disease, gastric infection, pertussis, peritonitis, 5 psoriasis, rheumatoid arthritis, sepsis, asthma, HIV and glomerulonephritis.
35. A polypeptide according to any one of claims 1 to 8, a nucleic acid molecule according to any one of claims 9 to 12, a vector according to claim 13, a host cell according to claim 14, a ligand according to claim 15 or claim 16, a compound according to any one of claims 17 to 19, or a pharmaceutical composition according to claim 32, for use in 10 the manufacture of a medicament for the treatment of a disease in which defensins are implicated.
36. A method of treating a disease in a patient, comprising administering to the patient a polypeptide according to any one of claims 1 to 8, a nucleic acid molecule according to any one of claims 9 to 12, a vector according to claim 13, a host cell according to claim 14, a ligand according to claim 15 or claim 16, a compound according to any one of 15 claims 17 to 19, or a pharmaceutical composition according to claim 32.
37. A method according to claim 36, wherein, for diseases in which the expression of the natural gene or the activity of the polypeptide is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, 20 nucleic acid molecule, vector, ligand, compound or composition administered to the patient is an agonist.
38. A method according to claim 36, wherein, for diseases in which the expression of the natural gene or activity of the polypeptide is higher in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, vector, ligand, compound or composition administered to the 25 patient is an antagonist.
39. A method of monitoring the therapeutic treatment of disease in a patient, comprising monitoring over a period of time the level of expression or activity of a polypeptide according to any one of claims 1 to 8, or the level of expression of a nucleic acid molecule according to any one of claims 9 to 12 in tissue from said patient, wherein altering said level of expression or activity over the period of time towards a control 30 level is indicative of regression of said disease.

40. A method for the identification of a compound that is effective in the treatment and/or diagnosis of disease, comprising contacting a polypeptide according to any one of claims 1 to 8, or a nucleic acid molecule according to any one of claims 9 to 12 with one or more compounds suspected of possessing binding affinity for said polypeptide or nucleic acid molecule, and selecting a compound that binds specifically to said nucleic acid molecule or polypeptide.
5
 41. A kit useful for diagnosing disease comprising a first container containing a nucleic acid probe that hybridises under stringent conditions with a nucleic acid molecule according to any one of claims 9 to 12; a second container containing primers useful for amplifying said nucleic acid molecule; and instructions for using the probe and primers for facilitating the diagnosis of disease.
10
 42. The kit of claim 41, further comprising a third container holding an agent for digesting unhybridised RNA.
 43. A kit comprising an array of nucleic acid molecules, at least one of which is a nucleic acid molecule according to any one of claims 9 to 12.
15
- one of claims 1 to 8; and a reagent useful for the detection of a binding reaction between said antibody and said polypeptide.
45. A transgenic or knockout non-human animal that has been transformed to express higher, lower or absent levels of a polypeptide according to any one of claims 1 to 8.
20
 46. A method for screening for a compound effective to treat disease, by contacting a non-human transgenic animal according to claim 45 with a candidate compound and determining the effect of the compound on the disease of the animal.

Figure 1: BLAST result against NCBI non-redundant database using SEQ ID NO: 6 (the INSP108 polypeptide).

BLASTP 2.2.2 [Jan-08-2002]

Reference: Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402.

Query= INSP108.ppp
(77 letters)

Database: All non-redundant GenBank CDS
translations+PDB+SwissProt+PIR+PRF
1,267,376 sequences; 405,046,914 total letters

Searching.....done

| Sequences producing significant alignments: | Score (bits) | E Value |
|--|-----------------|------------|
| ref NP_697019.1 defensin, beta 123; defensin, beta 23 [Homo sap...] | 51 | 4e-06 |
| ref XP_141520.1 similar to defensin, beta 123; defensin, beta 2... | 46 | 1e-04 |
| gb AAM93917.1 defensin beta 124 [Homo sapiens] | 39 | 0.012 |
| emb CAB72350.2 dJ1018D12.3 (a putative novel protein) [Homo sap...] | 39 | 0.016 |
| ref NP_473453.1 epididymus specific clone 42; chromosome 20 ope... | 39 | 0.016 |
| ref NP_660139.1 defensin beta 119; testis-specific beta-defensi... | 39 | 0.021 |
| sp Q95LI0 D118 MACMU Beta-defensin 118 precursor (Epididymal sec... | 37 | 0.079 |
| ref NP_631968.1 defensin beta 15 [Mus musculus] >gi 19171622 em... | 37 | 0.079 |
| ref NP_689464.1 defensin, beta 106; defensin, beta 6 [Homo sapi... | 35 | 0.18 |
| gb AAN33114.1 beta-defensin 106 [Homo sapiens] | 35 | 0.18 |

Figure 2: Alignment between INSP108 polypeptide sequence (SEQ ID NO:6) and defensin beta 123 (*Homo sapiens*).

```
>ref|NP_697019.1| defensin, beta 123; defensin, beta 23 [Homo sapiens]
sp|Q8N688|D123_HUMAN Beta-defensin 123 precursor (Beta-defensin 23) (DEFB-23)
gb|AAM93916.1| defensin beta 123 [Homo sapiens]
Length = 67


Score = 50.8 bits (120), Expect = 4e-06
Identities = 26/67 (38%), Positives = 33/67 (48%), Gaps = 10/67 (14%)

Query: 6 VLLALVVLNLLFYVPPGRSGPNVYIQQKIFASCWRLQGTCKPKCLKNEQRILCDTIHLCC 65
+LL L VL LL + PG + CW L G CR +C K E+ + C +CC
Sbjct: 4 LLLTLTVLLLLSQLTPGGT-----QRCWNLYGKCRYRCSKKERVYVYCINNMCC 53

Query: 66 VNPKYLP 72
V PKY P
Sbjct: 54 VKPKYQP 60
```


Figure 3: Sig P cleavage site prediction for INSP108.

>INSP108.pp



```
>INSP108.pp          length = 70
# Measure  Position  Value  Cutoff  signal peptide?
max. C      25      0.933   0.33    YES
max. Y      25      0.828   0.32    YES
```

```
# Most likely cleavage site between pos. 24 and 25: GRS-GP
```



```
>INSP108.pp
Prediction: Signal peptide
Signal peptide probability: 1.000
Signal anchor probability: 0.000
Max cleavage site probability: 0.906 between pos. 24 and 25
```

4/22

Figure 4: BLAST result against NCBI non-redundant database using SEQ ID NO: 14 (the INSP109 polypeptide).

BLASTP 2.2.2 (Jan-08-2002)

Reference: Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402.

Query= INSP109.ppp
(78 letters)

Database: All non-redundant GenBank CDS
translations+PDB+SwissProt+PIR+PRF
1,267,376 sequences; 405,046,914 total letters

Searching.....done

| Sequences producing significant alignments: | Score (bits) | E Value |
|---|-----------------|------------|
| dbj BAC37510.1 unnamed protein product [Mus musculus] | 88 | 3e-17 |
| ref NP_062702.1 defensin beta 4; beta defensin-4 [Mus musculus]... | 33 | 1.1 |
| emb CAA08905.1 beta defensin-2 [Capra hircus] | 31 | 3.3 |
| ref NP_348802.1 Uncharacterized protein, homolog HI1244 from Ha... | 31 | 4.3 |
| gb AAG10514.1 AF288371_1 beta-defensin 4 variant [Mus musculus] | 31 | 4.3 |
| emb CAD23115.1 blue cone opsin [Cottus kesslerii] | 30 | 7.4 |
| ref NP_689464.1 defensin, beta 106; defensin, beta 6 [Homo sapi... | 30 | 9.6 |
| gb AAN33114.1 beta-defensin 106 [Homo sapiens] | 30 | 9.6 |

5/22

Figure 5: Alignment between INSP109 polypeptide sequence (SEQ ID NO:14) and defensin beta 4 (*Mus musculus*).

```
>ref|NP_062702.1| defensin beta 4; beta defensin-4 [Mus musculus]
  sp|P82019|BD04_MOUSE Beta-defensin 4 precursor (BD-4) (mBD-4)
  gb|AAD38852.1|AF155882_1 beta defensin-4 [Mus musculus]
  gb|AAG02197.1|AF287475_1 beta-defensin 4 precursor [Mus musculus]
  dbj|BAB26051.1| unnamed protein product [Mus musculus]
  dbj|BAB26207.1| unnamed protein product [Mus musculus]
  Length = 63


Score = 32.7 bits (73), Expect = 1.1
Identities = 19/56 (33%), Positives = 27/56 (47%), Gaps = 1/56 (1%)

Query: 8 LLFFLVILLPSGKGFMFGNDGVKVRTCTSQKAVCFFGCPPGYRWIAFC-HNILSCCK 62
       LLF +++L S      F          TC + A+C+ CP +R I C H + CCK
Sbjct: 6 LLFTFLLVLLSPLAAFTQIINNPITCMTNGAICWGPCPTAFRQIGNCGHFKVRCCCK 61
```


6/22

Figure 6: Sig P cleavage site prediction for INSP109.

>INSP109.pp



```
>INSP109.pp          length = 70
# Measure  Position  Value  Cutoff  signal peptide?
max. C      22       0.849   0.33    YES
max. Y      22       0.854   0.32    YES
max. S       7        0.994   0.82    YES
mean S     1-21      0.953   0.47    YES
# Most likely cleavage site between pos. 21 and 22: GKG-MF
```



```
>INSP109.pp
Prediction: Signal peptide
Signal peptide probability: 0.999
Signal anchor probability: 0.001
Max cleavage site probability: 0.619 between pos. 21 and 22
```

Figure 7: Predicted nucleotide sequence of INSP108 with translation

1 ttgttccaaa agtttcacta gccatgcagc tccccgtctc ttcaaagctg cggagagagt
61 gactctccga tgagtcacag ctgtttctt gctgatttgt atggccacaa ggagcgtcct
m a t r s v
INSP108-F1

121 cttggccctc gtggccctta acttactctt ctatgttcca ccaggttagaa gtggaccCAA
l l a l v v l n l f y v p p g r s g p

181 tgtctacata caaaaaatct ttgcttcatg ttggcgactg caaggtactt gccggccAA
n v y i q k i f a s c w r l q g t c r p

241 atgtctaaaa aacgaacaat atcgtatttt gtgtgatact atacatttgt gctgtgtAAA
k c i k n e q y r i l c d t i h l c c v

301 cccaaaatat ttacctatac tgactggaa atagttgtga gtacctgaaa gctgttgctg
n p k y l p i l t g k

361 atttcctctg ggaacccaga tccctctcag ttgcaccatt cgattaaaac aatggcttA
421 gcctatcagt gttc

Position and sense of PCR primers →
Underlined: signal sequence

Figure 8: Nucleotide sequence with translation of INSP108 PCR product cloned using primers INSP108-CP1 and INSP108-CP2.

1 atggatgg ccacaaggag cgtccttgc gcctcggtgg tccttaactt acttttat
m a t r s v l l a l v v i n l l f y
INSP108-F1 →

61 gttccaccag gtagaagtgg acccaatgtc tacataaaaaaa aaatctttgc ttcatgttgg
v p p g r s g p n v y i q k i f a s c w

121 cgactgcaag gtacttgccg gccaaaatgt ctaaaaaacg aacaatatcg tattttgtgt
r l q g t c x p k c l k n e q y r i l c

181 gatactatac atttgtgctg tgtaaaccca aaatattttac ctatactgac tggaaatag
d t i h l c c v n p k y l p i l t g k
INSP108-R1 ←

241 ttgtg

Position and sense of PCR primers →

Figure 9: Map of pCR4-TOPO-INSP108

Molecule: pCR4-TOPO-INSPI08, 4202 bps DNA Circular

| Type | Start | End | Name | Description |
|--------|-------|------|----------|--------------------------------|
| MARKER | 205 | | M13R | M13 rev priming site |
| MARKER | 243 | | T3 | T3 priming site |
| MARKER | 295 | | CP2 | INSP108-CP2 |
| GENE | 533 | 303 | C cds | INSP108 cds |
| MARKER | 539 | | C CP1 | INSP108-CP1 |
| REGION | 539 | 295 | C Insert | INSP108-F1R1 PCR product |
| MARKER | 592 | | C T7 | T7 priming site |
| MARKER | 600 | | C M13F | M13 for priming site |
| GENE | 1404 | 2198 | Kan | Kanamycin resistance gene ORF |
| GENE | 2402 | 3262 | Amp | Ampicillin resistance gene ORF |
| MARKER | 3407 | | pUC ori | pUC origin |





Figure 10: Map of pDONR 221

Molecule: pDONR221, 4759 bps DNA Circular
 File Name: pDONR221.cm5

Description:

| Type | Start | End | Name | Description |
|--------|-------|------|-----------|------------------------------------|
| REGION | 295 | 268 | C rrnB T2 | transcription termination sequence |
| REGION | 470 | 427 | C rrnB T1 | transcription termination sequence |
| REGION | 536 | 553 | 21M13 | M13 Forward primer |
| REGION | 570 | 801 | attP1 | |
| GENE | 1197 | 1502 | ccdB | |
| GENE | 1844 | 2503 | Cm r | Chloramphenicol resistance gene |
| REGION | 2751 | 2982 | attP2 | |
| REGION | 3040 | 3023 | C M13 Rev | M13 Reverse primer |
| GENE | 3153 | 3962 | Kan r | |
| REGION | 4083 | 4756 | pUC ori | |



11/22

Figure 11: Map of expression vector pEAK12d

Molecule: pEAK12 d, 8760 bps DNA Circular
 File Name: pEAK12DEST.cm5

Description: Mammalian cell expression vector (plasmid ID 11345)

Molecule Features:

| Type | Start | End | Name | Description |
|--------|-------|------|-----------|----------------------------|
| REGION | 2 | 595 | | pmb-ori |
| GENE | 596 | 1519 | Amp | |
| REGION | 1690 | 2795 | EF-1alpha | |
| REGION | 2703 | 2722 | | position of pEAK12F primer |
| REGION | 2796 | 2845 | | MCS |
| MARKER | 2855 | | attR1 | |
| GENE | 3256 | 3915 | CmR | |
| GENE | 4257 | 4562 | ccdB | |
| MARKER | 4603 | | C attR2 | |
| REGION | 4733 | 4733 | | MCS |
| REGION | 4734 | 5162 | | poly A/splice |
| REGION | 4819 | 4848 | C | position of pEAK12R primer |
| GENE | 5781 | 5163 | C PUR | PUROMYCIN |
| REGION | 6005 | 5782 | C tK | tK promoter |
| REGION | 6500 | 6006 | C Ori P | |
| GENE | 8552 | 6500 | C EBNA-1 | |
| REGION | 8553 | 8752 | sv40 | |




Figure 12: Map of expression vector pDEST12.2

Molecule: pDEST 12.2, 7278 bps DNA Circular
 File Name: pDEST12-2.cm5

Description: Eukaryotic expression vector

| Type | Start | End | Name | Description |
|--------|-------|------|---------|-----------------------------------|
| REGION | 15 | 608 | CMV | CMV promoter |
| MARKER | 648 | | M13R | M13R primer |
| REGION | 687 | 706 | SP6 | SP6 promoter |
| REGION | 730 | 854 | attR1 | |
| GENE | 963 | 1622 | Cm | |
| GENE | 1964 | 2269 | ccdB | |
| REGION | 2310 | 2434 | attR2 | |
| GENE | 2484 | 2464 | C T7 | T7 promoter |
| MARKER | 2512 | | C 21M13 | 21M13 primer |
| REGION | 2784 | 3050 | pA | SV40 polyadenylation signal |
| REGION | 3176 | 3631 | f1 | f1 intergenic region |
| REGION | 3791 | 4099 | P SV40 | SV40 ori & early promoter |
| GENE | 4158 | 4952 | Neo | |
| REGION | 5016 | 5064 | pA | synthetic poly adenylation signal |
| GENE | 5475 | 6335 | Amp | |
| REGION | 6480 | 7153 | ori | pUC ori |




Figure 13: Map of pDONR221-INSP108-6HIS

Molecule: pDONR221-INSP108-6HIS, 2805 bps DNA Circular

| Type | Start | End | Name | Description |
|--------|-------|------|-----------------|------------------------------------|
| REGION | 295 | 268 | C rrnB T2 | transcription termination sequence |
| REGION | 470 | 427 | C rrnB T1 | transcription termination sequence |
| REGION | 536 | 553 | 21M13 | 21M13 primer |
| REGION | 570 | 651 | attL1 | |
| GENE | 677 | 925 | INSP108-6HIS-V1 | INSP108-6HIS ORF |
| REGION | 940 | 1028 | attL2 | |
| REGION | 1086 | 1070 | C M13 R | M13R primer |
| GENE | 1199 | 2008 | Kan r | |
| GENE | 2129 | 2802 | pUC ori | |




Figure 14: Map of pEAK12d-INSP108-6HIS

Molecule: pEAK12d-INSP108, 7198 bps DNA Circular

| Type | Start | End | Name | Description |
|--------|-------|------|-----------|---------------|
| REGION | 2 | 595 | pmb-ori | |
| GENE | 596 | 1519 | Amp | |
| REGION | 1690 | 2795 | EF-1alpha | |
| REGION | 2796 | 2845 | MCS' | |
| REGION | 2855 | 2874 | attB1 | |
| GENE | 2888 | 3139 | INSP108 | |
| REGION | 3144 | 3165 | attB2 | |
| REGION | 3171 | 3171 | 'MCS | |
| REGION | 3172 | 3600 | 'A | poly A/splice |
| GENE | 4219 | 3601 | C PUR | PUROMYCIN |
| REGION | 4443 | 4220 | C tK | tK promoter |
| REGION | 4938 | 4444 | C Ori P | |
| GENE | 6990 | 4938 | C EBNA-1 | |
| REGION | 6991 | 7190 | sv40 | |





Figure 15: Map of pDEST12.2-INSP108-6HIS

Molecule: pDEST12.2-INSP108-6HIS, 5884 bps DNA Circular

| Type | Start | End | Name | Description |
|--------|-------|------|--------------|-----------------------------|
| GENE | 15 | 537 | CMV promoter | |
| REGION | 648 | 665 | M13rev | M13R primer |
| REGION | 687 | 704 | SP6 | SP6 primer |
| REGION | 730 | 762 | attB1 | |
| GENE | 763 | 1011 | INSP108-6HIS | |
| REGION | 1015 | 1040 | attB2 | |
| REGION | 1090 | 1070 | C T7 | T7 promoter |
| REGION | 1119 | 1101 | C 21M13 | 21M13 primer |
| GENE | 1225 | 1587 | pA | SV40 polyadenylation signal |
| GENE | 1781 | 2237 | f1 | f1 intergenic region |
| GENE | 2301 | 2719 | P SV40 | SV40 ori & early promoter |
| GENE | 2764 | 3558 | Neo | |
| GENE | 3622 | 3670 | pA | poly adenylation signal |
| GENE | 4081 | 4941 | Amp | |
| GENE | 5090 | 5729 | ori | pUC ori |



16/22

Figure 16: Predicted nucleotide sequence of INSP109 with translation

1 atgaacctct gtctttctgc attactcttc ttccctggta tcttactgcc ttcaggaaaa
m n l c l s a l l f f l v i l l p s g k

61 ggtatgttg ggaatgatgg agtcaaagtt cgcacctgca cttagccagaa agccgtatgt
g m f g n d g v k v r t c t s q k a v c

121 ttcttcgggt gtccgccagg atacaggtgg attgcgttct gccacaatat tctgtcttgc
f f g c p p g y r w i a f c h n i l s c

181 tgtaaaaata tgacacgtt tcaaccccg caagccaaag atccatgggt tcatt
c k n m t r f q p p q a k d p w v h

Underlined= signal peptide

17/22

Figure 17: INSP109 coding exon organization in genomic DNA and position of PCR primers

| | | |
|--------------|--|------|
| | INSP109-exon1F | |
| Genomic DNA | 4448 ATGAACCTCTGTCTTCTGCATTACTCTTCTCCTGGTGATCTTACTGCC | 4497 |
| | | |
| INSP109 cdna | 101 ATGAACCTCTGTCTTCTGCATTACTCTTCTCCTGGTGATCTTACTGCC | 150 |
| | | |
| | INSP109-exon2F | |
| | INSP109-exon2F | |
| Genomic DNA | 4498 TTCAGgttaag.....ttcagGAAAAGGTATGTTGGGAATGATGGAGTC | 4958 |
| | >>> 426 >>>> | |
| INSP109 cdna | 151 TTCAG.....GAAAAGGTATGTTGGGAATGATGGAGTC | 185 |
| | >>> 426 >>>> | |
| Genomic DNA | 4959 AAGTTCGCACCTGCACTAGCCAGAAAGCCGTATGTTCTCGGGTGTCCG | 5008 |
| | | |
| INSP109 cdna | 186 AAGTTCGCACCTGCACTAGCCAGAAAGCCGTATGTTCTCGGGTGTCCG | 235 |
| | | |
| Genomic DNA | 5009 CCAGGATACAGGTGGATTGCGTTCTGCCACAATATTCTGTCTGCTGTAA | 5058 |
| | | |
| INSP109 cdna | 236 CCAGGATACAGGTGGATTGCGTTCTGCCACAATATTCTGTCTGCTGTAA | 285 |
| | | |
| INSP109 cdna | 286 AAATATGACACGTTCAACCCCCGCAAGCCAAAGATCCATGGGTTCAT | 335 |
| | | |
| Genomic DNA | 5109 AA | |
| | | |
| INSP109 cdna | 336 AA | |
| | — | |

Figure 18: Nucleotide sequence and translation of cloned INSP109 ORF

1 atgaacctct gtctttctgc attactcttc ttccctggta tcttactgcc ttcaggaaaa
m n l c l s a l l f f l v i l l p s g k
61 ggtatgttg ggaatgatgg agtcaaagtt cgcacctgca ctagccagaa agccgtatgt
g m f g n d g v k v r t c t s q k a v c
121 ttcttcgggt gtccgccagg atacaggtgg attgcgttct gccacaatat tctgtcttgc
f f g c p p g y r w i a f c h n i l s c
181 tgtaaaaata tgacacgttt tcaaccccg caagccaaag atccatgggt tcatta
c k n m t r f q p p q a k d p w v h

Figure 19: Map of pCR4-TOPO-INSP109

25 Nov 2003

Molecule Features

Molecule: pCR4-TOPO INSP109, 4193 bps DNA Circular
 File Name: 13984[1].cm5

Description: Ligation of inverted INSP109 assembled insert into pCR4-TOPO linear vector*

| Type | Start | End | Name | Description |
|--------|-------|------|----------|--------------------------------|
| MARKER | 205 | | M13R | M13 rev priming site |
| MARKER | 243 | | T3 | T3 priming site |
| REGION | 530 | 295 | C Insert | INSP109 assembled insert |
| GENE | 530 | 297 | C cds | INSP109 cds |
| MARKER | 583 | | C T7 | T7 priming site |
| MARKER | 591 | | C M13F | M13 for priming site |
| GENE | 1395 | 2189 | Kan | Kanamycin resistance gene ORF |
| GENE | 2393 | 3253 | Amp | Ampicillin resistance gene ORF |
| MARKER | 3398 | | pUC ori | pUC origin |





Figure 20: Map of pDONR221-INSPI09-6HIS

Molecule: pDONR221-INSPI09-6HIS, 2808 bps DNA Circular

| Type | Start | End | Name | Description |
|--------|-------|------|--------------|------------------------------------|
| REGION | 295 | 268 | C rrnB T2 | transcription termination sequence |
| REGION | 470 | 427 | C rrnB T1 | transcription termination sequence |
| REGION | 536 | 553 | 21M13 | 21M13 primer |
| REGION | 570 | 651 | attL1 | |
| GENE | 677 | 928 | INSPI09-6HIS | |
| REGION | 943 | 1031 | attL2 | |
| REGION | 1089 | 1073 | C M13 R | M13R primer |
| GENE | 1202 | 2011 | Kan r | |
| GENE | 2132 | 2805 | pUC ori | |



21/22

Figure 21: Map of pEAK12d-INSPI09-6HIS

Molecule: pEAK12d-INSPI09-6HIS, 7201 bps DNA Circular

| Type | Start | End | Name | Description |
|--------|-------|------|--------------|---------------|
| REGION | 2 | 595 | pmb-ori | |
| GENE | 596 | 1519 | Amp | |
| REGION | 1690 | 2795 | EF-lalpha | |
| REGION | 2796 | 2845 | MCS'' | |
| REGION | 2855 | 2874 | attB1 | |
| GENE | 2888 | 3142 | INSP109-6HIS | |
| REGION | 3147 | 3168 | attB2 | |
| REGION | 3174 | 3174 | 'MCS | |
| REGION | 3175 | 3603 | 'A | poly A/splice |
| GENE | 4222 | 3604 | C PUR | PUROMYCIN |
| REGION | 4446 | 4223 | C tk | tk promoter |
| REGION | 4941 | 4447 | C Ori P | |
| GENE | 6993 | 4941 | C EBNA-1 | |
| REGION | 6994 | 7193 | sv40 | |





Figure 22: Map of pDEST12.2-INSP109-6HIS

Molecule: pDEST12.2-INSP109-6HIS, 5887 bps DNA Circular

| Type | Start | End | Name | Description |
|--------|-------|------|--------------|-----------------------------|
| GENE | 15 | 537 | CMV promoter | |
| REGION | 648 | 665 | M13rev | M13R primer |
| REGION | 687 | 704 | SP6 | SP6 primer |
| REGION | 730 | 762 | attB1 | |
| GENE | 763 | 1014 | INSP109-6HIS | |
| REGION | 1018 | 1043 | attB2 | |
| REGION | 1093 | 1073 | C T7 | T7 promoter |
| REGION | 1122 | 1104 | C 21M13 | 21M13 primer |
| GENE | 1228 | 1590 | pA | SV40 polyadenylation signal |
| GENE | 1784 | 2240 | f1 | f1 intergenic region |
| GENE | 2304 | 2722 | P SV40 | SV40 ori & early promoter |
| GENE | 2767 | 3561 | Neo | |
| GENE | 3625 | 3673 | pA | poly adenylation signal |
| GENE | 4084 | 4944 | Amp | |
| GENE | 5093 | 5732 | ori | pUC ori |



INTERNATIONAL SEARCH REPORT

National Application No
PCT/GB2004/000101

| | | | | | |
|-------------------------------------|------------|-----------|------------|----------|-----------|
| A. CLASSIFICATION OF SUBJECT MATTER | | | | | |
| IPC 7 | C07K14/47 | C12N15/12 | G01N33/566 | C12Q1/68 | A61K38/17 |
| | A01K67/027 | | | | |

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, SEQUENCE SEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|------------------------|
| X | WO 02/04487 A (ADERMANN KNUT ;CONEJO GARCIA JOSE RAMON (DE); FORSSMANN WOLF GEORG) 17 January 2002 (2002-01-17) claims 11,27 --- SCHUTTE B C ET AL: "Discovery of five conserved beta-defensin gene clusters using a computational searching strategy" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, WASHINGTON, D.C., vol. 99, no. 4, 19 February 2002 (2002-02-19), pages 2129-2133, XP002250229 ISSN: 0027-8424 figure 1 --- -/- | 1,3, 5-14, 20-46 |
| X | | 1,3, 5-14, 20-46 |
| | | |

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search:

7 May 2004

Date of mailing of the international search report

15/06/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentzaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax. (+31-70) 340-3016

Authorized officer

Cupido, M

INTERNATIONAL SEARCH REPORT

I ional Application No
PCI/GB2004/000101

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. | | |
|----------|---|-----------------------|-------|-------|
| X | <p>HARDER J: "A PEPTIDE ANTIBIOTIC FROM HUMAN SKIN" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 387, 26 June 1997 (1997-06-26), page 861 XP002072639 ISSN: 0028-0836 the whole document</p> <p>---</p> | 1, 3, | 5-14, | 20-46 |
| P, X | <p>WO 03/024992 A (CASAVANT THOMAS L ;UNIV IOWA RES FOUND (US); JIA HONG PENG (US); S) 27 March 2003 (2003-03-27) se DEFB21, DEFB22 and DEFB23 figure 1; example 2</p> <p>---</p> | 1, 3, | 5-14, | 20-46 |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB2004/000101

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the International application and necessary to the claimed invention, the international search was carried out on the basis of:
 - a. type of material
 - a sequence listing
 - table(s) related to the sequence listing
 - b. format of material
 - in written format
 - in computer readable form
 - c. time of filing/furnishing
 - contained in the International application as filed
 - filed together with the International application in computer readable form
 - furnished subsequently to this Authority for the purpose of search
2. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2004/000101

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 21 and 26-30 are directed to a diagnostic method practised on the human/animal body, and claims 36-39 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds.
2. Claims Nos.: 15, 17-19 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/GB2004/000101

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.2

Claims Nos.: 15,17-19

Present claims 15 and 17-19 relate to a compound defined by reference to a desirable characteristic or property, namely that it binds specifically to the defensin polypeptide according to any one of claims 1-8. The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for no such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, no search has been carried out for those claims.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International

preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

National Application No

GB2004/000101

| Patent document cited in search report | | Publication date | | Patent family member(s) | | Publication date |
|--|---|------------------|--|---|--|--|
| WO 0204487 | A | 17-01-2002 | | AU 8964101 A CA 2427066 A1 WO 0204487 A2 EP 1299541 A2 ES 2197840 T1 JP 2004504017 T | | 21-01-2002 24-02-2003 17-01-2002 09-04-2003 16-01-2004 12-02-2004 |
| WO 03024992 | A | 27-03-2003 | | WO 03024992 A2 US 2003176652 A1 | | 27-03-2003 18-09-2003 |

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record.**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.